<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>HY Biochem</title><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 h1 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 28pt; }
 h2 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s1 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .p, p { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; margin:0pt; }
 .s2 { color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s3 { color: #010EFF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 12pt; }
 .s4 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s5 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s6 { color: #00B050; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s7 { color: black; font-family:Arial, sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s8 { color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s9 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s12 { color: #01F; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 12pt; }
 .s13 { color: #F00; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s14 { color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s15 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6.5pt; vertical-align: 3pt; }
 .s16 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6.5pt; vertical-align: 3pt; }
 .s17 { color: #F00; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s18 { color: #000AFF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 12pt; }
 .s19 { color: #0003FF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s20 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s21 { color: #00B050; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s22 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s23 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s24 { color: #FF0BF0; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s25 { color: black; font-family:Arial-BoldItalicMT, sans-serif; font-style: italic; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s26 { color: #000AFF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s27 { color: #00B050; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 9.5pt; }
 .s28 { color: #00B050; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s29 { color: #00B050; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; }
 .s30 { color: #0070C0; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s31 { color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s32 { color: black; font-family:Arial-BoldItalicMT, sans-serif; font-style: italic; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s34 { color: #202122; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; vertical-align: 1pt; }
 .s35 { color: #202122; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6.5pt; }
 .s36 { color: #202122; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6.5pt; }
 .s37 { color: #000AFF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s38 { color: #936; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s39 { color: #936; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 li {display: block; }
 #l1 {padding-left: 0pt; }
 #l1> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; }
 #l2 {padding-left: 0pt; }
 #l2> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l3 {padding-left: 0pt; }
 #l3> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l4 {padding-left: 0pt; }
 #l4> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l5 {padding-left: 0pt; }
 #l5> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l6 {padding-left: 0pt; }
 #l6> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l7 {padding-left: 0pt; }
 #l7> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l8 {padding-left: 0pt; }
 #l8> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l9 {padding-left: 0pt; }
 #l9> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l10 {padding-left: 0pt; }
 #l10> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l11 {padding-left: 0pt; }
 #l11> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l12 {padding-left: 0pt; }
 #l12> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l13 {padding-left: 0pt; }
 #l13> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l14 {padding-left: 0pt; }
 #l14> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l15 {padding-left: 0pt; }
 #l15> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l16 {padding-left: 0pt; }
 #l16> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l17 {padding-left: 0pt; }
 #l17> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l18 {padding-left: 0pt; }
 #l18> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l19 {padding-left: 0pt; }
 #l19> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l20 {padding-left: 0pt; }
 #l20> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l21 {padding-left: 0pt; }
 #l21> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l22 {padding-left: 0pt; }
 #l22> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l23 {padding-left: 0pt; }
 #l23> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l24 {padding-left: 0pt; }
 #l24> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l25 {padding-left: 0pt; }
 #l25> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l26 {padding-left: 0pt; }
 #l26> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l27 {padding-left: 0pt; }
 #l27> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l28 {padding-left: 0pt; }
 #l28> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l29 {padding-left: 0pt; }
 #l29> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l30 {padding-left: 0pt; }
 #l30> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l31 {padding-left: 0pt; }
 #l31> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l32 {padding-left: 0pt; }
 #l32> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l33 {padding-left: 0pt; }
 #l33> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l34 {padding-left: 0pt; }
 #l34> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l35 {padding-left: 0pt; }
 #l35> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l36 {padding-left: 0pt; }
 #l36> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l37 {padding-left: 0pt; }
 #l37> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l38 {padding-left: 0pt; }
 #l38> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l39 {padding-left: 0pt; }
 #l39> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l40 {padding-left: 0pt; }
 #l40> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l41 {padding-left: 0pt; }
 #l41> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l42 {padding-left: 0pt; }
 #l42> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l43 {padding-left: 0pt; }
 #l43> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l44 {padding-left: 0pt; }
 #l44> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l45 {padding-left: 0pt; }
 #l45> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l46 {padding-left: 0pt; }
 #l46> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l47 {padding-left: 0pt; }
 #l47> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l48 {padding-left: 0pt; }
 #l48> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l49 {padding-left: 0pt; }
 #l49> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l50 {padding-left: 0pt; }
 #l50> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l51 {padding-left: 0pt; }
 #l51> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l52 {padding-left: 0pt; }
 #l52> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l53 {padding-left: 0pt; }
 #l53> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l54 {padding-left: 0pt; }
 #l54> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l55 {padding-left: 0pt; }
 #l55> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l56 {padding-left: 0pt; }
 #l56> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l57 {padding-left: 0pt; }
 #l57> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; }
 #l58 {padding-left: 0pt; }
 #l58> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; }
 #l59 {padding-left: 0pt; }
 #l59> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l60 {padding-left: 0pt; }
 #l60> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l61 {padding-left: 0pt; }
 #l61> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l62 {padding-left: 0pt; }
 #l62> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l63 {padding-left: 0pt; }
 #l63> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l64 {padding-left: 0pt; }
 #l64> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l65 {padding-left: 0pt; }
 #l65> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l66 {padding-left: 0pt; }
 #l66> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l67 {padding-left: 0pt; }
 #l67> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l68 {padding-left: 0pt; }
 #l68> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l69 {padding-left: 0pt; }
 #l69> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l70 {padding-left: 0pt; }
 #l70> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l71 {padding-left: 0pt; }
 #l71> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l72 {padding-left: 0pt; }
 #l72> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l73 {padding-left: 0pt; }
 #l73> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l74 {padding-left: 0pt; }
 #l74> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l75 {padding-left: 0pt; }
 #l75> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l76 {padding-left: 0pt; }
 #l76> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l77 {padding-left: 0pt; }
 #l77> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l78 {padding-left: 0pt; }
 #l78> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l79 {padding-left: 0pt; }
 #l79> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l80 {padding-left: 0pt;counter-reset: n2 1; }
 #l80> li>*:first-child:before {counter-increment: n2; content: counter(n2, decimal)") "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l80> li:first-child>*:first-child:before {counter-increment: n2 0;  }
 #l81 {padding-left: 0pt; }
 #l81> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l82 {padding-left: 0pt; }
 #l82> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l83 {padding-left: 0pt; }
 #l83> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l84 {padding-left: 0pt; }
 #l84> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l85 {padding-left: 0pt; }
 #l85> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l86 {padding-left: 0pt; }
 #l86> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l87 {padding-left: 0pt; }
 #l87> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l88 {padding-left: 0pt; }
 #l88> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l89 {padding-left: 0pt; }
 #l89> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l90 {padding-left: 0pt; }
 #l90> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l91 {padding-left: 0pt; }
 #l91> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l92 {padding-left: 0pt; }
 #l92> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l93 {padding-left: 0pt; }
 #l93> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l94 {padding-left: 0pt; }
 #l94> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l95 {padding-left: 0pt; }
 #l95> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l96 {padding-left: 0pt; }
 #l96> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l97 {padding-left: 0pt; }
 #l97> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l98 {padding-left: 0pt; }
 #l98> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l99 {padding-left: 0pt;counter-reset: y1 1; }
 #l99> li>*:first-child:before {counter-increment: y1; content: counter(y1, decimal)") "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l99> li:first-child>*:first-child:before {counter-increment: y1 0;  }
 #l100 {padding-left: 0pt; }
 #l100> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l101 {padding-left: 0pt; }
 #l101> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l102 {padding-left: 0pt; }
 #l102> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l103 {padding-left: 0pt; }
 #l103> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l104 {padding-left: 0pt; }
 #l104> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l105 {padding-left: 0pt; }
 #l105> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l106 {padding-left: 0pt; }
 #l106> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l107 {padding-left: 0pt; }
 #l107> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l108 {padding-left: 0pt; }
 #l108> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l109 {padding-left: 0pt; }
 #l109> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l110 {padding-left: 0pt; }
 #l110> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l111 {padding-left: 0pt; }
 #l111> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l112 {padding-left: 0pt; }
 #l112> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l113 {padding-left: 0pt; }
 #l113> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l114 {padding-left: 0pt; }
 #l114> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l115 {padding-left: 0pt; }
 #l115> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l116 {padding-left: 0pt; }
 #l116> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l117 {padding-left: 0pt; }
 #l117> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l118 {padding-left: 0pt; }
 #l118> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l119 {padding-left: 0pt; }
 #l119> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l120 {padding-left: 0pt; }
 #l120> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l121 {padding-left: 0pt; }
 #l121> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l122 {padding-left: 0pt; }
 #l122> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l123 {padding-left: 0pt; }
 #l123> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l124 {padding-left: 0pt; }
 #l124> li>*:first-child:before {content: "■ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l125 {padding-left: 0pt; }
 #l125> li>*:first-child:before {content: "• "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l126 {padding-left: 0pt; }
 #l126> li>*:first-child:before {content: "• "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l127 {padding-left: 0pt; }
 #l127> li>*:first-child:before {content: "• "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l128 {padding-left: 0pt; }
 #l128> li>*:first-child:before {content: "- "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l129 {padding-left: 0pt; }
 #l129> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l130 {padding-left: 0pt; }
 #l130> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l131 {padding-left: 0pt; }
 #l131> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l132 {padding-left: 0pt; }
 #l132> li>*:first-child:before {content: "➔ "; color: black; font-family:"Arial Unicode MS", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l133 {padding-left: 0pt; }
 #l133> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l134 {padding-left: 0pt; }
 #l134> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l135 {padding-left: 0pt; }
 #l135> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l136 {padding-left: 0pt; }
 #l136> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l137 {padding-left: 0pt; }
 #l137> li>*:first-child:before {content: "o "; color: black; font-family:"Courier New", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 table, tbody {vertical-align: top; overflow: visible; }
</style></head><body><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 250pt;text-indent: 0pt;text-align: left;"><span><img width="89" height="92" alt="image" src="Image_001.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-top: 11pt;padding-left: 175pt;text-indent: -9pt;line-height: 122%;text-align: left;">MEHLMANMEDICAL HY BIOCHEMISTRY</h1><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 252pt;text-indent: 0pt;text-align: left;"><span><img width="90" height="95" alt="image" src="Image_002.jpg"/></span></p><h1 style="padding-top: 6pt;padding-left: 170pt;text-indent: 62pt;line-height: 122%;text-align: left;">YouTube @mehlmanmedical</h1><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 253pt;text-indent: 0pt;text-align: left;"><span><img width="89" height="95" alt="image" src="Image_003.jpg"/></span></p><h1 style="padding-top: 6pt;padding-left: 163pt;text-indent: 61pt;line-height: 122%;text-align: left;">Instagram @mehlman_medical</h1><h2 style="padding-top: 4pt;padding-left: 58pt;text-indent: 0pt;text-align: left;"><a name="a0">HY Biochemistry</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s1" style="padding-left: 58pt;text-indent: 0pt;line-height: 212%;text-align: left;">The purpose of this document is not to be a 600-page, long-winded textbook discussing every detail dating back to your high school bio days. The idea is to strike a balance between sufficient detail while staying as concise and HY as possible for USMLE (i.e., I’m aware some students want me to just cut to the chase with HY factoids; others want more in depth discussion of every mechanism). I will also make a separate doc specifically addressing more of the pedantic genetics stuff. Relax.</p><ul id="l1"><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">Student question showed DNA being replicated and they pointed to enzyme at replication fork; what’s the enzyme? <span class="s2">➔ </span>answer = helicase.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 10pt;text-align: left;">Question asks what is acted upon by DNA ligase to form a DNA sequence that aligns complimentary</p><p style="padding-top: 2pt;padding-left: 94pt;text-indent: 0pt;line-height: 25pt;text-align: left;">with the leading strand in DNA synthesis? <span class="s2">➔ </span>answer = Okazaki fragments; the lagging strand in DNA synthesis is composed of Okazaki fragments that are synthesized discontinuously and then amalgamated using DNA ligase.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 103pt;text-indent: 0pt;text-align: left;"><span><img width="479" height="225" alt="image" src="Image_004.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:451pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s3" style="padding-left: 102pt;padding-right: 101pt;text-indent: 0pt;line-height: 13pt;text-align: center;">HY DNA replication enzymes for USMLE</p></td></tr><tr style="height:13pt"><td style="width:113pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 36pt;padding-right: 35pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Enzyme</p></td><td style="width:338pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 145pt;padding-right: 145pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY points</p></td></tr><tr style="height:98pt"><td style="width:113pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">Topoisomerase</p></td><td style="width:338pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">topoisomerase inhibitors (aka DNA gyrase)</p></td></tr><tr style="height:13pt"><td style="width:113pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 36pt;padding-right: 35pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Primase</p></td><td style="width:338pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-   <span class="s5">Makes RNA primer at onset of DNA replication</span></p></td></tr><tr style="height:25pt"><td style="width:113pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-right: 17pt;text-indent: 0pt;text-align: right;">DNA polymerase III</p></td><td style="width:338pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:13pt"><td style="width:113pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-right: 19pt;text-indent: 0pt;line-height: 11pt;text-align: right;">DNA polymerase I</p></td><td style="width:338pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-   <span class="s5">Degrades RNA primer after DNA polymerase III acts</span></p></td></tr><tr style="height:37pt"><td style="width:113pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 32pt;text-indent: 0pt;text-align: left;">Telomerase</p></td><td style="width:338pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-left: 41pt;text-indent: -18pt;line-height: 106%;text-align: left;">-  <span class="s5">Lengthens ends of DNA strands to prevent degradation; aging is correlated with loss of strand length; telomerase upregulated in some</span></p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">cancers</p></td></tr><tr style="height:13pt"><td style="width:113pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 36pt;padding-right: 35pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Helicase</p></td><td style="width:338pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-   <span class="s5">Unwinds DNA template at replication fork</span></p></td></tr></table><ul id="l2"><li><p class="s5" style="padding-left: 41pt;padding-right: 33pt;text-indent: -18pt;line-height: 106%;text-align: left;">Causes nicks in DNA; allows for relief of strand tension; prevents supercoiling and strand breakage</p></li><li><p class="s6" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Fluoroquinolones <span style=" color: #000;">(e.g., levofloxacin, ciprofloxacin) are </span><span class="s7">prokaryotic</span></p></li><li><p class="s6" style="padding-left: 41pt;padding-right: 7pt;text-indent: -18pt;text-align: left;">Etoposide/teniposide <span class="s8">➔ </span><span style=" color: #000;">eukaryotic topoisomerase II inhibitors used as chemotherapeutic agents</span></p></li><li><p class="s6" style="padding-left: 41pt;padding-right: 9pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Irinotecan/topotecan <span class="s8">➔ </span><span style=" color: #000;">eukaryotic topoisomerase I inhibitors used as chemotherapeutic agents</span></p></li></ul><ul id="l3"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Synthesizes DNA 5’ <span class="s8">➔ </span>3’ using the RNA primer synthesized by primase</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;">3’ <span class="s8">➔ </span>5’ exonuclease proofreading ability</p></li></ul></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">82M + prostatitis + treated with pharmacologic agent for 10 days + now has sore ankle while metal detecting; Q asks, what’s the MOA of the drug he was treated with? <span class="s2">➔ </span>answer = inhibits DNA nicking; drug is fluoroquinolone (i.e., ciprofloxacin); frequent choice for prostatitis (and pyelonephritis); MOA</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 209%;text-align: justify;">is prokaryotic topoisomerase II/IV inhibitor (aka DNA gyrase); enzyme normally causes nicking in DNA to prevent supercoiling and breakage; HY adverse effect is tendonitis (e.g., Achilles); cannot be taken with divalent cations (i.e., foods containing calcium and iron <span class="s2">➔ </span>-J oral bioavailability of drug).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 9pt;text-align: left;">56M + lost in forest + eats mushrooms + dies; which of the following enzymes was most likely</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-bottom: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 194%;text-align: justify;">inhibited in this patient? <span class="s2">➔ </span>answer = RNA polymerase II; a-amanitin in death cap mushrooms inhibits RNA polymerase II (synthesizes mRNA).</p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:451pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="3"><p class="s3" style="padding-left: 102pt;padding-right: 101pt;text-indent: 0pt;line-height: 13pt;text-align: center;">RNA polymerases for USMLE</p></td></tr><tr style="height:13pt"><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Type</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Target</p></td><td style="width:322pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 134pt;padding-right: 134pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY point(s)</p></td></tr><tr style="height:62pt"><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">RNA polymerase I</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-right: 7pt;text-indent: 0pt;text-align: right;">rRNA</p></td><td style="width:322pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">nucleus)</p></td></tr><tr style="height:160pt"><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">RNA polymerase II</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">mRNA</p></td><td style="width:322pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:61pt"><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 10pt;padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">RNA polymerase III</p></td><td style="width:37pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 10pt;padding-right: 7pt;text-indent: 0pt;text-align: right;">tRNA</p></td><td style="width:322pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l4"><li><p class="s5" style="padding-left: 41pt;padding-right: 25pt;text-indent: -18pt;line-height: 106%;text-align: left;">Ribosomal RNA is a non-coding type of RNA that is the primary component of ribosomes</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;line-height: 106%;text-align: left;">Processing of rRNA into ribosomes occurs in nucleoli of the nucleus in eukaryotes and within the cytosol of prokaryotes (due to lack of</p></li></ul><ul id="l5"><li><p class="s5" style="padding-left: 41pt;padding-right: 17pt;text-indent: -18pt;line-height: 106%;text-align: left;">When DNA is transcribed into RNA, the RNA is first called hnRNA (heteronuclear RNA); three modifications then occur in the nucleus: 1) addition of 3’ poly-A tail; 2) addition of 5’ methylguanosine cap; 3) splicing out of introns; after these modifications, it is then called messenger RNA and exported to cytosol, where it is translated to protein</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 29pt;text-indent: -18pt;line-height: 106%;text-align: left;">mRNA can associate with p-bodies in the cytosol, which are “docking centers” where mRNA can be further processed and stored for future use</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 5pt;text-indent: -18pt;text-align: left;">RNA polymerase II + transcription factors bind to TATA box within the promoter sequence upstream of gene in order to commence transcription; if TATA box mutated <span class="s8">➔ </span>-J binding of RNA polymerase</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">a-amanitin in death cap mushrooms inhibits RNA polymerase II</p></li></ul><ul id="l6"><li><p class="s5" style="padding-left: 41pt;padding-right: 16pt;text-indent: -18pt;line-height: 106%;text-align: left;">As the mRNA codon sequence is read on the ribosome, transfer RNAs deliver amino acids and the growing peptide is synthesized</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 44pt;text-indent: -18pt;line-height: 106%;text-align: left;">tRNA anticodon sequence binds to complementary codon sequence of mRNA</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Different tRNAs carry different amino acids</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">42F + has colonic polyps + tests positive for <i>MLH1 </i>mutation + mom has Hx of duodenal and endometrial cancer; what’s the most likely mechanism associated with this family’s diagnosis? <span class="s2">➔ </span>answer = “microsatellite instability” or “defective mismatch repair”; Dx is Lynch syndrome (hereditary</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">non-polyposis colorectal cancer; HNPCC); associated with mutations in mismatch repair genes <i>MLH1, MSH2, MSH6, PMS2.</i></p></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;line-height: 206%;text-align: left;">Researcher is investigating a DNA repair process that is characterized by the deletion of an AGTC sequence within a DNA region rich in AGTC tandem repeats; he notices this DNA repair process is inhibited when he adds DNAse to the medium; Q asks which process this is <span class="s2">➔ </span>answer = slipped strand</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 10pt;text-align: left;">mispairing; student says wtf? <span class="s2">➔ </span>on the Step 1 NBME <span class="s2">➔ </span>sites rich in tandem sequences (e.g., AGTC)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">are prone to erroneous insertions/deletions of sequences; slipped strand mispairing can correct for these abnormalities; DNAse disrupts process since the repair requires a transient breakage of the phosphodiester bond, where the DNA ends are exposed and can be degraded.</p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:451pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s3" style="padding-left: 102pt;padding-right: 101pt;text-indent: 0pt;line-height: 14pt;text-align: center;">HY DNA repair types for USMLE</p></td></tr><tr style="height:13pt"><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Type</p></td><td style="width:317pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 132pt;padding-right: 131pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY point(s)</p></td></tr><tr style="height:49pt"><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Nucleotide-excision repair</p></td><td style="width:317pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:25pt"><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Base-excision repair</p></td><td style="width:317pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:62pt"><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 10pt;padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Mismatch repair</p></td><td style="width:317pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:25pt"><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Non-homologous end-joining</p></td><td style="width:317pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:49pt"><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 40pt;padding-right: 6pt;text-indent: -7pt;line-height: 106%;text-align: left;">Recombinational dsDNA repair</p></td><td style="width:317pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Fanconi anemia</p></td></tr><tr style="height:49pt"><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Slipped strand mispairing</p></td><td style="width:317pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l7"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Removal of bulky helical distortions</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;line-height: 106%;text-align: left;">The answer if the Q asks about pyrimidine-pyrimidine dimers (i.e., from UV light)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Xeroderma pigmentosum</p></li></ul><ul id="l8"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Removal of single base</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">The answer if the Q mentions glycosylases.</p></li></ul><ul id="l9"><li><p class="s5" style="padding-left: 41pt;padding-right: 25pt;text-indent: -18pt;line-height: 106%;text-align: left;">Mismatched bases in newly synthesized (unmethylated) DNA strand are removed</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 49pt;text-indent: -18pt;line-height: 106%;text-align: left;">The answer if the Q says anything about “microsatellite instability”</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Lynch syndrome (<i>HNPCC</i>)</p></li></ul><ul id="l10"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Amalgamates ends of two dsDNA fragments</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Ataxia-telangiectasia</p></li></ul><ul id="l11"><li><p class="s5" style="padding-left: 41pt;padding-right: 17pt;text-indent: -18pt;text-align: left;">Defect in dsDNA is repaired using complementary strands from homologous dsDNA</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">The answer if the Q asks about <i>BRCA </i>genes for breast cancer or</p></li></ul><ul id="l12"><li><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;line-height: 106%;text-align: left;">The answer if the Q mentions an erroneous insertion or deletion of DNA repeat sequences within sites rich in tandem repeats (i.e., an extra AGTC is inserted within a site rich in AGTC repeats)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Process is disrupted in the presence of DNAse</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">4M + congenital disorder characterized by mutation within intron sequence; which of the following processes is most likely to be disrupted in this patient? <span class="s2">➔ </span>answer = splicing; introns are sequences of DNA that do not eventually become protein; exons are sequences that can eventually be translated to</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 211%;text-align: left;">protein; introns play a role in alternative splicing; mutations within intron sequences are known to sometimes cause problems with splicing.</p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:451pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s3" style="padding-left: 102pt;padding-right: 101pt;text-indent: 0pt;line-height: 13pt;text-align: center;">HY DNA mutation types for USMLE</p></td></tr><tr style="height:13pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Type</p></td><td style="width:395pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 171pt;padding-right: 170pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY point(s)</p></td></tr><tr style="height:25pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Missense</p></td><td style="width:395pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-left: 23pt;text-indent: 0pt;text-align: left;">-   <span class="s5">Codon sequence is altered, resulting in new codon coding for different amino acid –</span></p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">i.e., one amino acid is substituted for another</p></td></tr><tr style="height:37pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Nonsense</p></td><td style="width:395pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l13"><li><p class="s5" style="padding-left: 41pt;padding-right: 7pt;text-indent: -18pt;line-height: 106%;text-align: left;">Codon sequence is altered such that a stop codon is formed, resulting in a truncated, non-functional protein</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Stop codons: <span style=" color: #F00;">UGA, UAA, UAG </span>– “U Go Away, U Are Away, U Are Gone”</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:13pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:395pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><span class="s9">-   </span>(Start codon in eukaryotes is <span style=" color: #00B050;">AUG</span>, which codes for methionine)</p></td></tr><tr style="height:86pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Silent</p></td><td style="width:395pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s7" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">same <span class="s5">amino acid – i.e., no change in protein primary sequence</span></p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">not so much as to permit incessant pathology)</p></td></tr><tr style="height:49pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Frameshift</p></td><td style="width:395pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">formed</p></td></tr><tr style="height:38pt"><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Splice-site</p></td><td style="width:395pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l14"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Codon sequence is altered at third position, resulting in new codon that codes for the</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 24pt;text-indent: -18pt;text-align: left;">“Wobble” refers to the mutational “leniency” of this third codon position, where mutation does not cause change in the amino acid coded for</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;line-height: 106%;text-align: left;">“Wobble” is nature’s way of striking a balance between potentially advantageous vs deleterious mutations (i.e., allowing just enough mutations to enable evolution but</p></li></ul><ul id="l15"><li><p class="s5" style="padding-left: 41pt;padding-right: 17pt;text-indent: -18pt;line-height: 106%;text-align: left;">Insertion/deletion of one or two bases, resulting in all following codons being read off-frame</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Effect is often truncated, non-functional protein, as a stop codon may be erroneously</p></li></ul><ul id="l16"><li><p class="s5" style="padding-left: 41pt;padding-right: 14pt;text-indent: -18pt;text-align: left;">The answer if Q mentions a mutation within an intron sequence, or if the Q says an intron was erroneously retained within the final mRNA (i.e., it wasn’t spliced out)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Etiology of some cases of �-thalassemia</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 206%;text-align: left;">Investigator is looking at a DNA locus many hundreds of bases away from a gene that causes upregulation of transcription of this gene; which of the following best describes this locus under investigation? <span class="s2">➔ </span>answer = enhancer; enhancers are DNA loci that may be near or far from a gene and</p><p style="padding-left: 76pt;text-indent: 0pt;line-height: 9pt;text-align: center;">cause upregulation of gene transcription; activators are proteins that bind to enhancers.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l17"><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: justify;">Silencers are the opposite of enhancers.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: justify;">Repressors are proteins that bind silencer loci and cause transcriptional downregulation.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: justify;">Investigator is looking at prokaryotic translation process; which of the following sequences facilitates binding of bacterial ribosome to mRNA; answer = Shine-Dalgarno sequence; student says, “Yeah I’ve heard of that before. Wtf is that?” <span class="s2">➔ </span>ribosomal binding site on prokaryotic mRNA; aligns start codon on the mRNA with the ribosome to initiate translation.</p><ul id="l18"><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: justify;">Prokaryotic ribosomes: 30s + 50s subunits of 70s (correct, doesn’t add up)</p><ul id="l19"><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;line-height: 25pt;text-align: justify;">23s rRNA is component of 50S that is partial binding site for 50S inhibitors (i.e., macrolides, clindamycin, chloramphenicol, and linezolid); mutations in 23s RNA represent one mechanism of microbial resistance to these agents.</p></li></ul></li><li><p style="padding-top: 9pt;padding-left: 130pt;text-indent: -18pt;text-align: justify;">Eukaryotic ribosomes: 40s + 60s subunits of 80s (correct, doesn’t add up)</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;text-align: left;">What is a chaperone protein? <span class="s2">➔ </span>answer = facilitates protein folding (asked as one-liner on USMLE).</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 198%;text-align: left;">46M + pancreatic cancer + peripheral wasting; Q asks, which cellular organelle is most likely increased in this patient’s muscle cells? <span class="s2">➔ </span>NBME answer = autophagic vacuoles; autophagy is a process via which cellular components are broken down in cachexia and starvation; TNF-a is responsible for</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">cachexia in the setting of malignancy (aka cachectic factor); wrong answers are smooth endoplasmic reticulum, rough endoplasmic reticulum, Golgi, mitochondria, and mitotic spindles.</p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:450pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s12" style="padding-left: 35pt;text-indent: 0pt;text-align: left;">USMLE-pertinent info regarding cellular organelles sans the superfluousness</p></td></tr><tr style="height:13pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 10pt;padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Organelle</p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 149pt;padding-right: 149pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY point(s)</p></td></tr><tr style="height:25pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 18pt;text-indent: -11pt;text-align: left;">Smooth endoplasmic reticulum (SER)</p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:110pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 18pt;padding-right: 8pt;text-indent: -8pt;text-align: left;">Rough endoplasmic reticulum (RER)</p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;text-align: justify;">the RER/cytosol (do <span class="s13">not </span>choose misfolded channel on cell surface)</p></td></tr><tr style="height:13pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 10pt;padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Free ribosomes</p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-   <span class="s5">Produce proteins that are used intracellularly (i.e., are not exocytosed)</span></p></td></tr><tr style="height:94pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 10pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">Golgi</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 19pt;text-indent: 0pt;text-align: left;"><span><img width="80" height="60" alt="image" src="Image_005.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:148pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 8pt;padding-left: 10pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">Mitochondrion</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 18pt;text-indent: 0pt;text-align: left;"><span><img width="84" height="67" alt="image" src="Image_006.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">inherited</p></td></tr><tr style="height:74pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 10pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">Centriole</p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">prevent formation.</p></td></tr><tr style="height:112pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 8pt;padding-left: 10pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">Nucleus</p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">but on Step 1 NBME)</p></td></tr><tr style="height:25pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 5pt;padding-left: 10pt;padding-right: 9pt;text-indent: 0pt;text-align: center;">Peroxisome</p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:13pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 10pt;padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Lysosome</p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-   <span class="s5">Contain hydrolytic enzymes for digestive processes</span></p></td></tr></table><ul id="l20"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Synthesizes steroids + some types of lipids</p></li><li><p class="s5" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;text-align: left;">Found notably in testes and adrenal glands (t steroid biosynthesis)</p></li></ul><ul id="l21"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Synthesizes proteins mostly for exocytosis (i.e., for use outside the cell)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 63pt;text-indent: -18pt;line-height: 106%;text-align: left;">COP II transports proteins anterograde from RER to Golgi for processing/modification</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">COP I transports proteins retrograde to RER from Golgi</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 23pt;text-indent: -18pt;line-height: 106%;text-align: justify;">If Q tells you trafficking of proteins to Golgi is impaired, the answer for what intracellular change we expect is “dilation of RER” (makes sense, since proteins are “retained” at RER)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: justify;">If you get a cystic fibrosis Q, the CFTR channel is misfolded and retained in</p></li></ul><ul id="l22"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Processes and packages proteins</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Clathrin-coated vesicles mediate transport between Golgi and endosomes</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">The answer for I-cell disease if they ask for location of the enzyme defect</p></li></ul><ul id="l23"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Site of aerobic respiration (Kreb cycle, electron transport chain)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 15pt;text-indent: -18pt;text-align: left;">Drugs that cause uncoupling/diminution of proton gradient in intermembrane space lead to t ratio of O2 consumed per ATP produced (i.e., t O2 consumption/ATP production ratio <span class="s8">➔ </span>more O2 needed to generate same amount of ATP <span class="s8">➔ </span>heat production)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 13pt;text-indent: -18pt;line-height: 106%;text-align: justify;">“Ragged red fibers” is buzzy term for mitochondrial disorder on USMLE; disorders are maternally inherited (i.e., males do not transmit disease to offspring); hypotonia, lactic acidosis, ear/eye problems are HY findings in vignettes</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 9pt;text-indent: -18pt;text-align: justify;">Heteroplasmy is varying severity of disease in patients with mitochondrial disorders due to differing fractions of diseased mitochondrial genes</p></li></ul><ul id="l24"><li><p class="s5" style="padding-left: 41pt;padding-right: 14pt;text-indent: -18pt;line-height: 106%;text-align: left;">Produce mitotic spindles, which are composed of microtubules and form during M-phase of cell cycle</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 12pt;text-indent: -18pt;line-height: 106%;text-align: left;">HY microtubule inhibitors for Step 1: griseofulvin, mebendazole, taxanes (docetaxel, paclitaxel), colchicine, vincristine, vinblastine; the taxanes are the odd ones out because they hyperstabilize microtubules; the others</p></li></ul><ul id="l25"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Eukaryotes only</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Site of DNA replication and transcription to RNA</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 20pt;text-indent: -18pt;line-height: 109%;text-align: left;">Nucleolus is site within nucleus where rRNA is synthesized; “prominent nucleoli” in Q means t protein synthesis and t cancer grade (i.e., # of mitoses)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 7pt;text-indent: -18pt;line-height: 111%;text-align: left;">t nuclear/cytosplasm ratio (e.g., if Q says it approaches 1:1) indicates high cancer <i>grade </i>– i.e., indicates t mitoses</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Nuclear envelope proteins are phosphorylated during mitosis (ridiculous</p></li></ul><ul id="l26"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Very long-chain and branched-chain fatty acid synthesis</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Refsum disease, adrenoleukodystrophy, Zellweger syndrome</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:25pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:38pt"><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">Proteasome</p></td><td style="width:351pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l27"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Answer for where Strep pneumo killing is initiated (hydrolytic enzymes)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Lysosomal enzyme deficiencies <span class="s8">➔ </span>many diseases (discussed later)</p></li></ul><ul id="l28"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Site of intracellular protein breakdown</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Ubiquitination of proteins targets them for lysosomes</p></li><li><p class="s5" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Muscle atrophy entails t ubiquitination of proteins (NBME)</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-bottom: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: justify;">34F + undergoing chemotherapy; which of the following cell types in this patient is most likely to be adversely impacted by this management? <span class="s2">➔ </span>answer = crypts of gut epithelium (any answer that is a labile cell characterized by rapid turnover); crypts are site of gut stem cells.</p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:461pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="3"><p class="s3" style="padding-left: 172pt;padding-right: 171pt;text-indent: 0pt;line-height: 13pt;text-align: center;">Cell types for USMLE</p></td></tr><tr style="height:13pt"><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Cell type</p></td><td style="width:148pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY examples</p></td><td style="width:249pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 101pt;padding-right: 100pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY points</p></td></tr><tr style="height:37pt"><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">Labile</p></td><td style="width:148pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: left;">Gut epithelium, hair follicles, skin, germ cells, bone marrow</p></td><td style="width:249pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:37pt"><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 9pt;text-indent: 10pt;line-height: 106%;text-align: left;">Stable (quiescent)</p></td><td style="width:148pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Hepatocytes, lymphocytes</p></td><td style="width:249pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:25pt"><td style="width:64pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">Permanent</p></td><td style="width:148pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Neurons, RBCs, skeletal/cardiac</p><p class="s5" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">muscle</p></td><td style="width:249pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-top: 6pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">-   <span class="s5">Always in G0; regenerate from stem cells</span></p></td></tr></table><ul id="l29"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Remain in G1; never enter G0 (quiescent phase)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 5pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Most affected by chemotherapy because of rapid turnover</p></li></ul><ul id="l30"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Enter G1 from G0 when stimulated</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 5pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Regeneration of liver <span class="s8">➔ </span>answer = “enter G1 from G0”</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 199%;text-align: left;">23M + consumes energy drink; which of the following irreversible enzymes is most likely to demonstrate increased activity? <span class="s2">➔ </span>answer = pyruvate kinase (of glycolysis).</p><p class="s14" style="padding-left: 112pt;text-indent: 0pt;line-height: 12pt;text-align: left;">o <span class="p">An “easy” way to remember the irreversible enzymes in glycolysis is that they are enzyme #s</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 79pt;text-indent: 0pt;text-align: center;">1, 3, 9 – i.e., hexokinase/glucokinase (#1), PFK-1 (#3), pyruvate kinase (#9).</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 192%;text-align: left;">21M + goes three weeks without food; breakdown of which of the following most likely explains his ability to maintain stable blood glucose levels? <span class="s2">➔ </span>answer = skeletal muscle protein; glucogenic amino acids will be liberated by muscle <span class="s2">➔ </span>converted to glucose by the liver; muscle lacks glucose-6- phosphatase so does not directly produce glucose via gluconeogenesis.</p></li><li><p style="padding-top: 2pt;padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">22F + goes for a run; Q asks which enzyme will most likely be activated initially by exercise in this patient; answer = phosphorylase kinase, which will phosphorylate and activate glycogen phosphorylase, the main enzyme that removes glucose-1-phosphate (G1P) units from long glycogen branches and chains. In other words, before glycogen phosphorylase can do its job, it first needs to be phosphorylated and activated by phosphorylase kinase. After the glycogen branch has enough G1P units removed where it is now only four G1P units in length, the first debranching enzyme 1,4- glucosidase removes three of these units, leaving only one left. The second debranching enzyme 1,6- glucosidase removes the final G1P unit.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 16pt;text-indent: 0pt;text-align: left;"><span><img width="700" height="344" alt="image" src="Image_007.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-top: 5pt;padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">17F + frequent thirst and urination + markedly elevated serum glucose and ketones + serum pH of 7.1; following administration of insulin; activity of which enzyme is increased? <span class="s2">➔ </span>answer = glucokinase; glucokinase is the hexokinase equivalent in the liver and is upregulated by insulin; hexokinase is found elsewhere in the body and not upregulated by insulin; compared to hexokinase,</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">glucokinase has t Km and t Vmax, meaning that it has less affinity for glucose and greater capacity to handle it; this makes sense, since the liver should not preferentially process glucose over other cells in the body (e.g., muscle, brain); when serum glucose levels have risen high enough, the liver can act as a buffer to process glucose into glycogen (glycogenesis).</p><table style="border-collapse:collapse;margin-left:67.61pt" cellspacing="0"><tr style="height:15pt"><td style="width:93pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 9pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Enzyme</p></td><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 9pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Where</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="text-indent: 0pt;text-align: center;">Km</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="text-indent: 0pt;text-align: center;">Vmax</p></td><td style="width:132pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 18pt;padding-right: 17pt;text-indent: 0pt;text-align: center;">Upregulated by insulin?</p></td></tr><tr style="height:14pt"><td style="width:93pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 9pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Hexokinase</p></td><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 9pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Mostly ubiquitous</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="text-indent: 0pt;text-align: center;"> J</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="text-indent: 0pt;text-align: center;"> J</p></td><td style="width:132pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 18pt;padding-right: 17pt;text-indent: 0pt;text-align: center;">No</p></td></tr><tr style="height:15pt"><td style="width:93pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 9pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Glucokinase</p></td><td style="width:94pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 1pt;padding-left: 9pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Liver + �-islets</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 1pt;text-indent: 0pt;text-align: center;">t</p></td><td style="width:67pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 1pt;text-indent: 0pt;text-align: center;">t</p></td><td style="width:132pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 18pt;padding-right: 17pt;text-indent: 0pt;text-align: center;">Yes</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-top: 10pt;padding-left: 94pt;text-indent: -18pt;line-height: 213%;text-align: left;">19F + eats meal; which of the following molecules is most likely to stimulate glycolysis in this patient; answer = AMP; AMP + ADP stimulate glycolysis; ATP, NADH, citrate, and alanine inhibit glycolysis.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 211%;text-align: left;">61F + eats meal; which of the following molecules is most likely to upregulate the rate-limiting step of glucose utilization in this patient; answer = fructose-2,6-bisphosphate.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 58pt;text-indent: 0pt;text-align: left;"><span><img width="611" height="266" alt="image" src="Image_008.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l31"><li><p style="padding-top: 5pt;padding-left: 130pt;text-indent: -18pt;text-align: justify;">PFK-1 is the rate-limiting step of glycolysis. F2,6-BP is a positive allosteric regulator of PFK-1.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 130pt;text-indent: 0pt;line-height: 213%;text-align: justify;">When insulin is high (fed state), some of F6P from glycolysis, rather than simply proceeding forward through glycolysis to F1,6-BP, is instead shunted into a side pathway to make F2,6- BP, which then positively allosterically regulates PFK-1.</p></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">47F + goes for a run; which of the following combinations best reflects glycogen phosphorylase in this patient (answers are combinations of phosphorylated vs dephosphorylated, active vs inactive); answer = phosphorylated + active. Glycogen phosphorylase breaks down glycogen (fasting state). Glycogen synthase builds up glycogen (fed state). Insulin dephosphorylates. Glucagon phosphorylates.</p><ul id="l32"><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">Fed state (t insulin): enzymes dephosphorylated.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">Fasting state (J. insulin): enzymes phosphorylated.</p><ul id="l33"><li><p style="padding-top: 10pt;padding-left: 166pt;text-indent: -18pt;text-align: left;">1<span class="s15">st</span><span class="s16"> </span>step: “Are we fed or fasting?”</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 166pt;text-indent: -18pt;text-align: left;">2<span class="s15">nd</span><span class="s16"> </span>step: “Would we expect a given enzyme to be active or inactive in this setting?”</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 166pt;text-indent: -18pt;text-align: left;">3<span class="s15">rd</span><span class="s16"> </span>step: “Is insulin up or down?”</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">4<span class="s15">th</span><span class="s16"> </span>step: If insulin is up, then enzyme is dephosphorylated. If insulin is down, then enzyme is phosphorylated.</p></li></ul></li></ul></li><li><p style="padding-top: 2pt;padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">27F + eats turkey dinner; which of the following combinations, in terms of inactive vs active, phosphorylated vs dephosphorylated, best reflects her phosphofructosekinase-2? <span class="s2">➔ </span>answer = active</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 11pt;text-align: left;">+ dephosphorylated; scenario is fed state (t insulin), enzyme upregulates glycolysis, so we expect it to</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;text-align: left;">be active in fed state. Since insulin is up, we choose dephosphorylated.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 77pt;text-indent: 0pt;text-align: left;"><span><img width="593" height="405" alt="image" src="Image_009.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-top: 5pt;padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">36F + type I diabetic + self-administers insulin; which of the following best explains the reduction of serum glucose in this patient? <span class="s2">➔ </span>answer = dephosphorylation of glycogen synthase; insulin upregulates GLUT4 on adipose tissue and skeletal muscle, yes, but it also upregulates glucokinase in the liver <span class="s2">➔ </span>liver acts as a buffer in the setting of increased serum glucose <span class="s2">➔ </span>glucose converted over to glycogen secondary to the dephosphorylation and activation of glycogen synthase by insulin.</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">Student says “Oh em gee. I thought it was just GLUT4.” Yeah, I know. Incredible.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;text-align: left;">Research group is investigating a protein in RBCs that shifts the Hb-O2 dissociation curve to the right.</p><p style="padding-top: 2pt;padding-left: 94pt;text-indent: 0pt;line-height: 25pt;text-align: left;">It is concluded that this molecule can be synthesized from a glycolytic intermediate via an RBC enzyme called bisphosphoglycerate mutase; which of the following glycolytic substrates is most likely the precursor to the RBC protein? <span class="s2">➔ </span>answer = 1,3-bisphosphoglycerate (1,3-BPG). The RBC protein is 2,3-BPG. Some 1,3-BPG from glycolysis is converted to 2,3-BPG inside the RBC via</p><p style="padding-top: 9pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">bisphosphoglycerate mutase.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 60pt;text-indent: 0pt;text-align: left;"><span><img width="590" height="97" alt="image" src="Image_010.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-top: 5pt;padding-left: 94pt;text-indent: -18pt;line-height: 192%;text-align: left;">20M + low Hb + high reticulocyte count + high indirect bilirubin + high RBC 2,3-BPG; which enzyme is deficient? <span class="s2">➔ </span>answer = pyruvate kinase deficiency; second most common cause of hemolysis due to an enzyme deficiency (after G6PD deficiency); pyruvate kinase converts phosphoenol pyruvate <span class="s2">➔ </span>pyruvate as last step of glycolysis; if decreased production of pyruvate, then decreased ATP</p><p style="padding-left: 94pt;text-indent: 0pt;text-align: left;">production <span class="s2">➔ </span>decreased activity of Na/K-ATPase pumps on RBC <span class="s2">➔ </span>cannot pump out sodium <span class="s2">➔</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-bottom: 3pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">cellular swelling + lysis (hemolysis); wrong answer is glyceraldhyde-3-phosphate dehydrogenase deficiency (would mean decreased 1,3-BPG, and ultimately decreased 2,3-BPG).</p><p style="padding-left: 85pt;text-indent: 0pt;text-align: left;"><span><img width="524" height="567" alt="image" src="Image_011.jpg"/></span></p></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;text-align: left;">10-month-old boy + 3<span class="s15">rd</span><span class="s16"> </span>percentile for length and weight + hypotonia + hypoglycemia + lactic acidosis</p><p style="padding-top: 2pt;padding-left: 94pt;text-indent: 0pt;line-height: 25pt;text-align: left;">+ hyperalaninemia; Q asks which enzyme is deficient; answer = pyruvate carboxylase; enzyme needed to convert pyruvate to oxaloacetate (OAA) as an early step for gluconeogenesis (so -J glucose); if less pyruvate is converted to OAA, then more pyruvate is shunted to alanine (pyruvate + glutamate <span class="s2">f-➔ </span>a-KG + alanine, via ALT and B6); more pyruvate is also converted to lactate via lactate dehydrogenase.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 25pt;text-align: left;">Experiment performed with brown adipose tissue; discovery shows a leak of H<span class="s15">+</span><span class="s16"> </span>ions inward across the inner mitochondrial membrane; Q asks, most likely effect on oxidative phosphorylation and energy metabolism? <span class="s2">➔ </span>answer = “increased ratio of oxygen consumption to ATP generated”; normally H<span class="s15">+</span><span class="s16"> </span>in intermembrane space moves through Complex V (ATP synthase) in order to produce ATP, but if H<span class="s15">+</span></p><p style="padding-top: 9pt;padding-left: 94pt;text-indent: 0pt;line-height: 206%;text-align: left;">leaks back across the inner membrane without going through Complex V (i.e., as a result of an upcoupling agent such as thermogenin in brown fat), more oxygen is needed to achieve the same # of ATP produced <span class="s2">➔ </span>generates heat.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="591" height="226" alt="image" src="Image_012.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: justify;">45M + wood worker + exposed to preservative for the wood that increases heat production in his cells; which of the following mechanisms best describes this process? <span class="s2">➔ </span>answer = “uncoupling of oxidative phosphorylation”; 2,4-dinitrophenol is a preservative for wood that is best known for</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">dissipating the proton gradient required for oxidative phosphorylation (electron transport chain).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l34"><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">Uncoupling agents include 2,4-<span class="s17">D</span>initrophenol, <span class="s17">E</span>thanol, <span class="s17">A</span>spirin, <span class="s17">TH</span>ermogenin (<span class="s17">DEATH</span>).</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">Rotenone inhibits Complex I (NADH dehydrogenase).</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">Antimycin A inhibits Complex III.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 198%;text-align: left;">Carbon monoxide (CO) inhibits Cytochrome a3 component of Complex IV (cytochrome c oxidase).</p></li></ul></li><li><p style="padding-top: 4pt;padding-bottom: 3pt;padding-left: 94pt;text-indent: -18pt;line-height: 213%;text-align: left;">2M + diminished mental status + family recently moved to winter lodge with old ventilator + carboxyhemoglobin elevated; which of the following steps is inhibited in this patient?</p><p style="padding-left: 98pt;text-indent: 0pt;text-align: left;"><span><img width="522" height="120" alt="image" src="Image_013.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l35"><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 204%;text-align: left;">Answer = G; CO inhibits Cyt a3 component of Complex IV (cytochrome c oxidase). Yes, I know. Outrageous. But it’s not our opinion that matters. It’s on a retired Step 1 NBME, so just know it.</p></li></ul></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: justify;">40M + working with paint thinner + vomiting + blurry vision + serum pH 7.27 + high-anion gap; Q asks for the pharmacologic treatment? <span class="s2">➔ </span>answer = fomepizole; diagnosis is methanol toxicity; methanol is in paint thinner; Alcohol dehydrogenase converts methanol to formaldehyde, which can cause</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">blindness and death; fomepizole inhibits this conversion by inhibiting alcohol dehydrogenase.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 79pt;text-indent: 0pt;text-align: left;"><span><img width="584" height="289" alt="image" src="Image_014.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">Neonate + has defect in fatty acid oxidation + physical exam shows no abnormalities; Q asks, what’s the next best step in diagnosis? <span class="s2">➔ </span>answer = “check serum acylcarnitine concentrations”; acylcarnitines are produced during the movement of fatty acids from the cytosol to the mitochondria</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">via the carnitine shuttle; low acylcarnitines suggests carnitine deficiency; normal acylcarnitines suggests medium- or long-chain acylCoA dehydrogenase (MCAD/LCAD) deficiency; affected children</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">will have <b>hypoketotic hypoglycemia </b>(i.e., low ketones and low glucose), since ketones cannot be produced without effective beta-oxidation; ketones are produced via the assembly of acetyl-CoA units; the latter are liberated during the breakdown of fatty acids via beta-oxidation. In other words:</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 13pt;text-align: left;">-J beta-oxidation <span class="s2">➔ </span>-J acetyl-CoA <span class="s2">➔ </span>-J ketogenesis. And since acetyl-CoA is a positive allosteric</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-bottom: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 217%;text-align: left;">regulator of pyruvate carboxylase (enzyme used in gluconeogenesis, as discussed earlier), if acetyl- CoA is -J, then glucose production is -J.</p><p style="padding-left: 78pt;text-indent: 0pt;text-align: left;"><span><img width="584" height="458" alt="image" src="Image_015.jpg"/></span></p></li><li><p style="padding-top: 11pt;padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">Researcher is conducting study on pyruvate carboxylase; which of the following molecules is found to increase activity of this enzyme? <span class="s2">➔ </span>answer = acetyl-CoA.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 10pt;text-align: left;">2M + hepatosplenomegaly + Hx of cardiopulmonary arrest following hypoglycemic episode + -J serum</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 197%;text-align: left;">glucose + -J serum ketones + administration of medium-chain triglycerides improves his condition; diagnosis? <span class="s2">➔ </span>answer = long-chain acyl-CoA dehydrogenase (LCAD) deficiency; patient has hypoketotic hypoglycemia, so the answer you want to look for is either carnitine, MCAD, or LCAD deficiency; since</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">medium-chain TGAs improved his condition, you know it can’t be MCAD deficiency (because he wouldn’t be able to process them), so LCAD deficiency is correct; for carnitine deficiency, neither</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">medium- or long-chain TGAs would improve the condition because the carnitine shuttle would be defective (cannot move fatty acids from cytosol to mitochondria).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">3M + disorder characterized by inability of epinephrine to liberate fatty acids for energy; Q asks, which hormone is likely deficient in this patient? <span class="s2">➔ </span>answer = hormone-sensitive lipase (HSL); HSL is catabolic and required to move TGAs from the adipocyte into the blood; it has increased activity in</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 214%;text-align: left;">the setting of higher levels of epinephrine, cortisol, and/or glucagon. In contrast, lipoprotein lipase (LPL) is anabolic and moves TGAs from the blood into the adipocyte; it has increased activity with higher levels of insulin. Other HY points: deficiency of LPL or apolipoprotein C-II causes familial hyperchylomicronemia (t TGAs <i>and </i>LDL); fibrates (e.g., fenofibrate, gemfibrozil) upregulate LPL activity and are most effective at J. serum TGAs.</p></li><li><p style="padding-bottom: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 199%;text-align: left;">3M + acanthocytes seen on blood smear + intestinal biopsy shows large clear droplets within the enterocytes; Dx? <span class="s2">➔ </span>answer = abetalipoproteinemia; J. apolipoprotein-B48 <span class="s2">➔ </span>chylomicrons fail to exit enterocytes.</p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:461pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s3" style="padding-left: 126pt;padding-right: 125pt;text-indent: 0pt;line-height: 13pt;text-align: center;">Apolipoprotein HY points for USMLE</p></td></tr><tr style="height:13pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 2pt;padding-right: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Apolipoprotein</p></td><td style="width:387pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 170pt;padding-right: 170pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY points</p></td></tr><tr style="height:25pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 2pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">B-48</p></td><td style="width:387pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:12pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 2pt;padding-right: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">B-100</p></td><td style="width:387pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-   <span class="s5">Binds to LDL receptor; enables clearance of cholesterol from blood</span></p></td></tr><tr style="height:25pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 2pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">C-II</p></td><td style="width:387pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:25pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;text-indent: 0pt;text-align: center;">E</p></td><td style="width:387pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:25pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;text-indent: 0pt;text-align: center;">A</p></td><td style="width:387pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l36"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Required to move chylomicrons out of the enterocytes into lymphatics/circulation</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Deficient in abetalipoproteinemia (acanthocytes; clear droplets in enterocytes)</p></li></ul><ul id="l37"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Cofactor for lipoprotein lipase (LPL)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Deficient in familial hyperchylomicronemia (or deficiency of LPL)</p></li></ul><ul id="l38"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Mediates particle uptake by the liver</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Deficient in familial dysbetalipoproteinemia</p></li></ul><ul id="l39"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Major protein component of HDL</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Deficient in hypoalphaproteinemia (Tangier disease)</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse" cellspacing="0"><tr style="height:15pt"><td style="width:475pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="3"><p class="s18" style="padding-left: 133pt;padding-right: 133pt;text-indent: 0pt;line-height: 13pt;text-align: center;">HY familial dyslipidemias for USMLE</p></td></tr><tr style="height:13pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 39pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Condition</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Mechanism</p></td><td style="width:206pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 76pt;padding-right: 76pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY point(s)</p></td></tr><tr style="height:50pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 51pt;padding-right: 11pt;text-indent: -38pt;line-height: 106%;text-align: left;">Hyperchylomicronemia (AR)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 35pt;padding-right: 5pt;text-indent: -29pt;line-height: 106%;text-align: left;">Deficiency of lipoprotein lipase or Apolipoprotein C-II</p></td><td style="width:206pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:86pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 50pt;text-indent: -35pt;line-height: 106%;text-align: left;">Hypercholesterolemia (AD)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 14pt;padding-right: 13pt;text-indent: 0pt;text-align: center;">Deficiency (heterozygous) or absence (homozygous) of LDL receptor or Apo B-100</p></td><td style="width:206pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">functional LDL receptor)</p></td></tr></table><ul id="l40"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">t chylomicrons + TGAs</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Pancreatitis (abdo, not chest, pain)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Xanthomas</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Plasma appears “creamy”</p></li></ul><ul id="l41"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">t LDL</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;line-height: 106%;text-align: left;">LDL usually 3-400 in heterozygotes, with MI/death in 30-40s (answer = deficiency of functional LDL receptor)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;text-align: left;">LDL usually 700-1000 in homozygotes, with MI in teens (answer = absence of</p></li></ul><p style="text-indent: 0pt;text-align: left;"/></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 199%;text-align: left;">14F + LDL of 280 mg/dL + father died of MI in his early-40s; what’s the mechanism for this patient’s condition? <span class="s2">➔ </span>answer = deficiency of LDL receptor; Dx is familial hypercholesterolemia.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:46.25pt" cellspacing="0"><tr style="height:13pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:206pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-   <span class="s5">Xanthomas</span></p></td></tr><tr style="height:25pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: -30pt;line-height: 12pt;text-align: left;">Dysbetalipoproteinemia (90% AR)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Deficiency of Apo-E</p></td><td style="width:206pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:25pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 50pt;padding-right: 11pt;text-indent: -33pt;line-height: 12pt;text-align: left;">Hypertriglyceridemia (AD)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">t Hepatic production of VLDL</p></td><td style="width:206pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:25pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Hypoalphaproteinemia</p><p class="s5" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">(Tangier disease)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Deficiency of Apo-A1</p></td><td style="width:206pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s9" style="padding-top: 6pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">-   <span class="s5">,j, HDL</span></p></td></tr></table><ul id="l42"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">t LDL + t TGAs</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Xanthomas, MI</p></li></ul><ul id="l43"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">t TGAs</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Pancreatitis</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">Investigator is studying vancomycin-resistant bacterial strain; after many generations of propagation, vancomycin-sensitivity is observed at a frequency of one per 200 cells; what’s the mechanism for loss of resistance? <span class="s2">➔ </span>answer = “plasmid loss”; most antibiotics resistance genes are located on the bacterial <i>plasmid</i>.</p><ul id="l44"><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 196%;text-align: left;">Plasmids have three main components: 1) origin of replication (where DNA replication is initiated), 2) polylinker (site where endonucleases act), 3) antibiotic resistance gene.</p></li><li><p style="padding-top: 2pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">Cloning is process of replicating (“cloning”) genetic material up to 10k base pairs. Process is:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l45"><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">Cleave out polylinker + insert desired gene of interest to be cloned (i.e., the gene you want to clone replaces the polylinker you’ve cleaved out).</p></li><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">Incubate plasmid with bacteria <span class="s2">➔ </span>bacteria then acquire the plasmid containing both the desired gene to be cloned and the antibiotic resistance gene.</p></li><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;text-align: left;">Incubate bacteria with antibiotic <span class="s2">➔ </span>only bacteria replicating the plasmid survive.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 166pt;text-indent: -18pt;text-align: left;">Extract out the cloned/desired DNA/protein from bacteria cells containing plasmid.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: justify;">Researcher develops toxin that causes inhibition of GTPase activity of G-alpha-s G proteins; which would most likely increase in a cell as a result of this toxin? <span class="s2">➔ </span>answer = cAMP; GTPases normally function to shut off G-protein function; if GTPase activity is impaired (e.g., in cancer), there is</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">constitutive (continual; increased) activity of the G-protein.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l46"><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 204%;text-align: left;">G-proteins are incredibly annoying concept if you’re seeing this concept for first time, but you need to know three classes for USMLE and how agonism/antagonism causes intracellular changes:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 58pt;text-indent: 0pt;text-align: left;"><span><img width="626" height="356" alt="image" src="Image_016.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-top: 3pt;padding-left: 130pt;text-indent: -18pt;line-height: 187%;text-align: left;">Agonism of G-alpha-q G proteins <span class="s2">➔ </span>increases phospholipase C, inositol 1,4,5-triphosphate (IP3), and diacylglycerol (yes, you need to know all three).</p></li><li><p style="padding-top: 1pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">Agonism of G-alpha-I <span class="s2">➔ </span>inhibits adenylyl cyclase <span class="s2">➔ </span>decreases cAMP.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">Agonism of G-alpha-s <span class="s2">➔ </span>activates adenylyl cyclase <span class="s2">➔ </span>increases cAMP.</p></li><li><p style="padding-top: 10pt;padding-left: 130pt;text-indent: -18pt;line-height: 188%;text-align: left;">Receptors for G-alpha-q: <span class="s19">HAV</span>e <span class="s19">1 </span>or <span class="s19">3 M</span>&amp;<span class="s19">M</span>s <span class="s2">➔ </span>Histamine 1, Alpha 1, Vasopressin 1, Muscarinic 1, Muscarinic 3.</p><ul id="l47"><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">In other words, if you give phenylephrine (alpha 1 agonist), you’re agonizing G- alpha-q, so the answer would be “increased IP3,” or “increased diacylglycerol.”</p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">Likewise, if you give diphenhydramine (H1 blocker), the answer would be “decreased IP3,” or “decreased phospholipase C activity.”</p></li></ul></li><li><p style="padding-top: 1pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">Receptors for G-alpha-i: <span class="s19">MAD2</span>s <span class="s2">➔ </span>Muscarinic 2, Alpha 2, Dopamine 2.</p><ul id="l48"><li><p style="padding-top: 10pt;padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">In other words, if you give methyldopa or clonidine (alpha 2 agonists), the answer is “decreased cAMP.”</p></li><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;text-align: left;">Likewise, if you give haloperidol (D2 blocker), the answer is “increased cAMP.”</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 204%;text-align: left;">Receptors for G-alpha-s: Beta 1, Beta 2, Dopamine 1, Histamine 2, Vasopressin 2 (essentially memorize both aforementioned mnemonics, and then the receptors that don’t fit into either you know are G-alpha-s).</p><ul id="l49"><li><p style="padding-top: 3pt;padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">In other words, for isoproterenol (beta 1 and 2 agonist), the answer is “increased cAMP.”</p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">Likewise, for propranolol (beta 1 and 2 antagonist), the answer is “decreased cAMP.”</p></li></ul></li></ul></li><li><p style="padding-top: 2pt;padding-left: 94pt;text-indent: -18pt;text-align: left;">Researcher studying influenza virus and antigenic shift; which of the following mechanisms best</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 187%;text-align: left;">explains this process? <span class="s2">➔ </span>answer = “reassortment”; antigenic shift <span class="s2">➔ </span>pandemics <span class="s2">➔ </span>reassortment of viral segments; antigenic drift <span class="s2">➔ </span>epidemics <span class="s2">➔ </span>point mutations in hemagglutinin and/or neuraminidase.</p></li><li><p style="padding-top: 2pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">13M + yellow eyes following treatment for infection + blood smear shows precipitated hemoglobin within RBCs; what’s the most likely mechanism for this condition? <span class="s2">➔ </span>“increased RBC membrane oxidation”; Dx is glucose-6-phosphate dehydrogenase (G6PD) deficiency; X-linked recessive; due to</p><p style="padding-top: 2pt;padding-bottom: 3pt;padding-left: 94pt;text-indent: 0pt;line-height: 214%;text-align: left;">deficient NADPH production via the HMP shunt; NADPH is a reducing agent that --1 oxidation of RBC membranes; patients have t hemolysis with certain drugs (i.e., sulfa, dapsone, hydroxychloroquine), infections, and, famously, fava beans. Blood smear shows degmacytes (bite cells) and Heinz bodies (precipitated, oxidized hemoglobin).</p><p style="padding-left: 78pt;text-indent: 0pt;text-align: left;"><span><img width="574" height="265" alt="image" src="Image_017.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;text-align: left;">19F + enzyme deficiency + increased indirect bilirubin; which enzyme is most likely deficient in this</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 187%;text-align: justify;">patient? <span class="s2">➔ </span>answer = pyruvate kinase deficiency <span class="s2">➔ </span>RBC cannot make sufficient ATP to drive Na out of the cell <span class="s2">➔ </span>water stays with sodium <span class="s2">➔ </span>RBC swelling <span class="s2">➔ </span>lysis; second most common cause of hemolysis due to an enzyme deficiency (after G6PD deficiency); pyruvate kinase deficiency is AR so can occur in</p><p style="padding-top: 2pt;padding-left: 94pt;text-indent: 0pt;text-align: justify;">females; G6PD (XR) only presents in males.</p></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">12M + Hx of recurrent Staph infections + dihydrorhodamine test confirms diagnosis; the deficient enzyme in this patient acts on which of the following as a substrate? <span class="s2">➔ </span>answer = molecular oxygen; diagnosis is NADPH oxidase deficiency (chronic granulomatous disease); nitroblue tetrazolium assay</p><p style="padding-top: 1pt;padding-bottom: 3pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">now obsolete and is the wrong answer on one of the Step 1 NBMEs (dihydrorhodamine test being correct); NADPH oxidase required as initial enzyme in order to ultimately generate sufficient H<span class="s20">2</span>O<span class="s20">2</span><span class="s1"> </span>to overwhelm catalase (+) organisms; even though the latter generate catalase, which breaks down H<span class="s20">2</span>O<span class="s20">2</span>, healthy individuals produce enough H<span class="s20">2</span>O<span class="s20">2</span><span class="s1"> </span>via respiratory burst pathway to outpower these pathogens. Molecular oxygen (O2) is the substrate of NADPH oxidase; should be noted that myeloperoxidase deficiency leading to insufficient generation of halide-hydroxyl radicals (bleach; hypochlorous acid) is equally HY on NBME yet underemphasized in other resources. NADPH is a reducing agent used in a variety of reactions produced via the G6PD pathway (HMP shunt).</p><p style="padding-left: 62pt;text-indent: 0pt;text-align: left;"><span><img width="582" height="498" alt="image" src="Image_018.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;text-align: left;"><span><img width="524" height="167" alt="image" src="Image_019.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-top: 5pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: justify;">6-month-old boy + enlarged tongue + hypotonia + cardiomegaly + muscle biopsy shows increased glycogen; Q asks which enzyme is deficient <span class="s2">➔ </span>answer = alpha-1-4-glucosidase (aka lysosomal acid maltase); diagnosis is Pompe syndrome (glycogen storage disease type II).</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: justify;">4-month-old boy + 2-month Hx of frequent crying and tremulousness presenting a few hours after feeds + massive hepatomegaly + hypoglycemia + lactic acidosis; which enzyme is deficient? <span class="s2">➔ </span>answer</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 10pt;text-align: left;">= glucose-6-phosphatase; Dx is von Gierke (glycogen storage disease type I); classically presents as</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;text-align: left;">young child with hepato-/hepatosplenomegaly, lactic acidosis, and hypoglycemia.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><h2 style="padding-left: 94pt;text-indent: -18pt;text-align: left;"><a name="a1">Glycogen storage diseases</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l50"><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">All autosomal recessive and can present with hepatomegaly</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:450pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="3"><p class="s18" style="padding-left: 150pt;padding-right: 150pt;text-indent: 0pt;line-height: 13pt;text-align: center;">Glycogen storage diseases</p></td></tr><tr style="height:13pt"><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Disease</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Enzyme deficiency</p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 11pt;padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY points</p></td></tr><tr style="height:37pt"><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">Type I (Von Gierke)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Glucose-6-phosphatase</p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s13" style="padding-left: 11pt;padding-right: 10pt;text-indent: 0pt;text-align: center;">Lactic acidosis</p><p class="s5" style="padding-left: 11pt;padding-right: 10pt;text-indent: 0pt;line-height: 12pt;text-align: center;">Hypoglycemia, jaundice, hepatomegaly; “super sick kid with glycogen storage disease”</p></td></tr><tr style="height:25pt"><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">Type II (Pompe)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 24pt;padding-right: 12pt;text-indent: -11pt;line-height: 12pt;text-align: left;">Debranching a1,4-glucosidase (lysosomal acid maltase)</p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-top: 6pt;padding-left: 11pt;padding-right: 10pt;text-indent: 0pt;text-align: center;">Cardiomyopathy, <span class="s5">hepatomegaly</span></p></td></tr><tr style="height:25pt"><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">Type III (Cori)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Debranching a1,6-glucosidase</p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s21" style="padding-left: 13pt;text-indent: 0pt;text-align: left;">No lactic acidosis <span class="s5">(in contrast to von Gierke);</span></p><p class="s5" style="padding-left: 10pt;text-indent: 0pt;line-height: 11pt;text-align: left;">“not so sick kid with glycogen storage disease”</p></td></tr><tr style="height:37pt"><td style="width:92pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 6pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">Type V (McArdle)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 6pt;padding-right: 6pt;text-indent: 28pt;line-height: 106%;text-align: left;">Myophosphorylase (glycogen muscle phosphorylase)</p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 8pt;padding-right: 4pt;text-indent: 24pt;line-height: 106%;text-align: left;">Patient usually adolescent or adult; severe cramping/rhabdo after intense exercise,</p><p class="s5" style="padding-left: 53pt;text-indent: 0pt;line-height: 11pt;text-align: left;">but normal serum lactate</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li><li><h2 style="padding-left: 94pt;text-indent: -18pt;text-align: left;"><a name="a2">Lysosomal storage diseases</a></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s14" style="padding-left: 112pt;text-indent: 0pt;text-align: left;">o <span class="p">All AR except for Fabry and Hunter (XR).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:17.93pt" cellspacing="0"><tr style="height:15pt"><td style="width:531pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="4"><p class="s18" style="padding-left: 187pt;padding-right: 187pt;text-indent: 0pt;line-height: 13pt;text-align: center;">Lysosomal storage diseases</p></td></tr><tr style="height:13pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Disease</p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Enzyme deficiency</p></td><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 14pt;padding-right: 13pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Buildup product(s)</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 86pt;padding-right: 86pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY points</p></td></tr><tr style="height:61pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 10pt;padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">I-cell</p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 106%;text-align: left;">N-acetylglucosamine- 1-phosphotransferase</p></td><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 10pt;padding-left: 14pt;padding-right: 13pt;text-indent: 0pt;text-align: center;">Many lysosomal enzymes</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 7pt;text-indent: -18pt;line-height: 106%;text-align: left;">-  Cannot synthesize mannose-6-phosphate at the Golgi; M6P needed to target lysosomal enzymes to the lysosomes; instead, lysosomal enzymes are secreted</p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">into cytosol + serum</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:17.93pt" cellspacing="0"><tr style="height:98pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s7" style="padding-right: 13pt;text-indent: 0pt;line-height: 11pt;text-align: right;">go<span class="s5">, the answer is cytosol/plasma/serum</span></p></td></tr><tr style="height:37pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">Gaucher</p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Glucocerebrosidase</p></td><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 14pt;padding-right: 13pt;text-indent: 0pt;text-align: center;">Glucocerebroside</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:37pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">Tay-Sachs</p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Hexosaminidase A</p></td><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 14pt;padding-right: 13pt;text-indent: 0pt;text-align: center;">GM<span class="s22">2</span><span class="s23"> </span>ganglioside</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:86pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">Niemann-Pick</p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Sphingomyelinase</p></td><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 14pt;padding-right: 13pt;text-indent: 0pt;text-align: center;">Sphingomyelin</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:25pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Metachromatic</p><p class="s5" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">leukodystrophy</p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Arylsulfatase A</p></td><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 14pt;padding-right: 13pt;text-indent: 0pt;text-align: center;">Cerebroside sulfate</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">-  Progressive neurologic decline</p></td></tr><tr style="height:37pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">Krabbe</p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Galactocerebrosidase</p></td><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 44pt;text-indent: -18pt;text-align: left;">Galactocerebroside, psychosine</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:37pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">Fabry</p><p class="s24" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">(XR)</p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">a-galactosidase A</p></td><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 14pt;padding-right: 13pt;text-indent: 0pt;text-align: center;">Ceramide trihexoside</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:49pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">Hurler</p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">a-L-iduronidase</p></td><td style="width:134pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" rowspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s9" style="padding-left: 60pt;text-indent: -47pt;text-align: left;">Glycosaminoglycans (GAGs) – i.e.,</p><p class="s9" style="padding-left: 13pt;text-indent: 0pt;text-align: left;">Dermatan + heparan sulfates</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:62pt"><td style="width:74pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">Hunter</p><p class="s24" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">(XR)</p></td><td style="width:106pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">Iduronate sulfatase</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l51"><li><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;line-height: 106%;text-align: left;">Course facial features, joint contractures, hepatomegaly, recurrent ear infections</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 18pt;text-indent: -18pt;line-height: 106%;text-align: left;">If the USMLE Q asks for the location of the error/problem, Golgi is the answer</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 7pt;text-indent: -18pt;line-height: 106%;text-align: left;">If the Q asks for where the enzymes <i>can’t go</i>, the answer is lysosome</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 17pt;text-indent: -41pt;text-align: right;">If the Q asks for where the enzymes <i>do</i></p></li></ul><ul id="l52"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Avascular necrosis of the hip</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 25pt;text-indent: -18pt;line-height: 12pt;text-align: left;">“crumpled tissue paper” (lipid-laded) macrophages</p></li></ul><ul id="l53"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Cherry red spot on macula (blindness)</p></li><li><p class="s13" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">No hepatosplenomegaly</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Neurodegeneration</p></li></ul><ul id="l54"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Cherry red spot on macula (blindness)</p></li><li><p class="s21" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Yes, hepatosplenomegaly</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 9pt;text-indent: -18pt;line-height: 106%;text-align: left;">Niemann-Pick is a longer name than Tay- Sachs, and hepatosplenomegaly is a long word, so Niemann-Pick is the one with hepatosplenomegaly</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Neurodegeneration</p></li></ul><ul id="l55"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Aka Globoid cell leukodystrophy</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Globoid cells (giant, multinucleated cells)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Neurodegeneration</p></li></ul><ul id="l56"><li><p class="s5" style="padding-left: 41pt;padding-right: 13pt;text-indent: -18pt;line-height: 106%;text-align: left;">Angiokeratomas (small, red/purple dots on the skin due to capillary dilation)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Heart and/or renal problems</p></li></ul><ul id="l57"><li><p class="s5" style="padding-left: 41pt;padding-right: 17pt;text-indent: -18pt;text-align: left;">Gargoyle-like facies, stridor, aggressive behavior</p></li><li><p class="s21" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Yes, clouded corneas</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">More severe form of Hunter</p></li></ul><ul id="l58"><li><p class="s5" style="padding-left: 41pt;padding-right: 17pt;text-indent: -18pt;line-height: 106%;text-align: left;">Gargoyle-like facies, stridor, aggressive behavior</p></li><li><p class="s13" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">No clouded corneas</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;line-height: 12pt;text-align: left;">“Hunters can see the X” <span class="s8">➔ </span>Therefore XR and no clouded corneas</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">4M + coarse facial features + contractures of large joints + markedly elevated plasma lysosomal enzyme levels; Q asks, what’s the most likely mechanism for this condition? <span class="s2">➔ </span>answer = “abnormal targeting of enzymes to lysosomes”; diagnosis is I-cell disease; as discussed, mechanism is inability of</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">the Golgi to make mannose-6-phosphate, which is required for proper targeting of lysosomal hydrolases to the lysosomes for storage; if they can’t go to the lysosomes, they are secreted into the plasma.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 199%;text-align: left;">Researcher is investigating the primary structure of a molecule that is defective in osteogenesis imperfecta; which amino acid is likely to be most abundant in this molecule? <span class="s2">➔ </span>answer = glycine;</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">primary structure of collagen is Gly-X-Y, where glycine composes one-third of collagen; X and Y are usually proline or lysine, which are then frequently hydroxylated to become hydroxyproline and hydroxylysine. For some reason the USMLE is known to ask about collagen synthesis:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><span><img width="742" height="442" alt="image" src="Image_020.jpg"/></span></p></li><li><h2 style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;text-align: left;"><a name="a3">Collagen disorders</a><span class="p">:</span></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:36.65pt" cellspacing="0"><tr style="height:15pt"><td style="width:497pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="4"><p class="s18" style="padding-left: 195pt;padding-right: 195pt;text-indent: 0pt;line-height: 13pt;text-align: center;">Collagen disorders</p></td></tr><tr style="height:25pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 3pt;padding-right: 3pt;text-indent: 0pt;text-align: center;">Collagen</p><p class="s4" style="padding-left: 3pt;padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: center;">type</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-top: 6pt;padding-left: 22pt;text-indent: 0pt;text-align: left;">Where found</p></td><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-top: 6pt;padding-left: 7pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Disease(s)</p></td><td style="width:213pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-top: 6pt;padding-left: 84pt;padding-right: 84pt;text-indent: 0pt;text-align: center;">HY points</p></td></tr><tr style="height:141pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">I</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;text-indent: 0pt;text-align: center;">Bone,</p><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 106%;text-align: center;">Late wound healing (white in color),</p><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 106%;text-align: center;">t tensile strength compared to type III</p></td><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 7pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Osteogenesis imperfecta (OI)</p></td><td style="width:213pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="123" height="56" alt="image" src="Image_021.jpg"/></span></p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">osteopetrosis</p></td></tr><tr style="height:37pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 22pt;text-indent: 0pt;text-align: left;">II</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 9pt;padding-right: 8pt;text-indent: 0pt;line-height: 106%;text-align: center;">Cartilage, Intervertebral discs,</p><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Vitreous humor</p></td><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 7pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Stickler syndrome</p></td><td style="width:213pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;">-  Congenital hearing loss</p></td></tr><tr style="height:25pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 21pt;text-indent: 0pt;text-align: left;">III</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Blood vessels,</p><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Early wound healing</p></td><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 7pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Ehlers-Danlos (vascular type)</p></td><td style="width:213pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">-  Hyperextensible skin/joints</p></td></tr></table><ul id="l59"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Fractures at different stages of healing</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Often mistaken for child abuse</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 20pt;text-indent: -18pt;line-height: 106%;text-align: left;">Blue sclerae (too easy; often omitted from Qs)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 13pt;text-indent: -18pt;line-height: 106%;text-align: left;">Conductive hearing loss (malformation of ossicles)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">If ruled out OI + child abuse, think</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:36.65pt" cellspacing="0"><tr style="height:126pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">(pink in color)</p><p class="s5" style="padding-top: 1pt;padding-left: 11pt;padding-right: 10pt;text-indent: 0pt;line-height: 106%;text-align: center;">--1 tensile strength compared to type I</p></td><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:213pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="padding-left: 82pt;text-indent: 0pt;text-align: left;"><span><img width="64" height="86" alt="image" src="Image_022.jpg"/></span></p></td></tr><tr style="height:145pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 3pt;padding-right: 3pt;text-indent: 0pt;text-align: center;">IV</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 17pt;text-indent: -11pt;line-height: 106%;text-align: left;">Basement membrane (kidney, alveoli)</p></td><td style="width:135pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">Alport, Goodpasture</p></td><td style="width:213pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 4pt;text-indent: 0pt;line-height: 106%;text-align: left;">+ hematuria; linear immunofluorescence pattern on biopsy</p><p style="padding-left: 63pt;text-indent: 0pt;text-align: left;"><span><img width="112" height="77" alt="image" src="Image_023.jpg"/></span></p></td></tr></table><ul id="l60"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Easy bruising</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Aortic dissection/regurgitation</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Mitral valve prolapse</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 48pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Circle of Willis berry (saccular) aneurysms</p></li></ul><ul id="l61"><li><p class="s5" style="padding-left: 41pt;padding-right: 24pt;text-indent: -18pt;text-align: left;">Alport (XR; <i>mutation in </i>type IV collagen); eye/ear problems in male with hematuria</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;line-height: 106%;text-align: left;">Goodpasture (<i>Abs against </i>type IV collagen); male 20s-40s with hemoptysis</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 192%;text-align: left;">12F + tall and lanky + myopia on school visual acuity exam + thrombotic episode; Dx? <span class="s2">➔ </span>answer = homocystinuria (AR); usually due to deficiency of cystathionine synthase; homocystine = two</p><p style="padding-top: 2pt;padding-left: 94pt;text-indent: 0pt;line-height: 211%;text-align: left;">homocysteines bound together; Q will be Marfanoid body habitus in school-age kid with thrombotic episode +/- a lens dislocation; B6 can be used as Tx in some patients.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 61pt;text-indent: 0pt;text-align: left;"><span><img width="585" height="59" alt="image" src="Image_024.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">13M + seizure + lens dislocation two years ago + serum cystathionine is decreased; what is most likely to be increased in this patient? <span class="s2">➔ </span>answer = methionine; shunting of homocysteine to methionine in this case.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">31M + tall + flat feet + pectus excavatum + mid-systolic click; the abnormal molecule in this patient is best described as which of the following? <span class="s2">➔ </span>answer = “glycoprotein that forms a sheath around elastin” (fibrillin); Dx is Marfan syndrome; AD; <i>FBN1/2 </i>genes on chromosome 15; fibrillin <span class="s25">is not</span></p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 211%;text-align: left;">related to collagen (it stabilizes elastin); tall, lanky stature; mitral valve prolapse + aortic regurg (myxomatous degeneration) + aortic dissection (cystic medial necrosis) can be seen; scoliosis;</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">arachnodactyly (long fingers); pes planus (flat feet); chest wall abnormalities (pectus excavatum/carinatum; abnormal hair distribution).</p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:451pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="3"><p class="s3" style="padding-left: 102pt;padding-right: 101pt;text-indent: 0pt;text-align: center;">Frequently confused connective tissue proteins</p></td></tr><tr style="height:13pt"><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 2pt;padding-right: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Molecule</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 86pt;padding-right: 85pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Structure</p></td><td style="width:182pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 42pt;text-indent: 0pt;line-height: 11pt;text-align: left;">HY disease associations</p></td></tr><tr style="height:74pt"><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 2pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">Collagen</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/><td style="width:182pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:74pt"><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 2pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">Elastin</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/><td style="width:182pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;">-  William syndrome</p></td></tr><tr style="height:25pt"><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 5pt;padding-left: 2pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">Fibrillin</p></td><td style="width:220pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-  Glycoprotein that forms a sheath around</p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">elastin</p></td><td style="width:182pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 5pt;padding-left: 23pt;text-indent: 0pt;text-align: left;">-  Marfan syndrome</p></td></tr></table><ul id="l62"><li><p class="s5" style="padding-top: 5pt;padding-left: 41pt;text-indent: -18pt;text-align: left;">Gly-X-Y primary structure</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Hydroxylation + glycosylation</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Triple-helical structure</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 25pt;text-indent: -18pt;line-height: 106%;text-align: left;">Cleavage of non-helical terminal end- groups</p></li></ul><ul id="l63"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Osteogenesis imperfecta (type I)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Stickler (type II)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 27pt;text-indent: -18pt;line-height: 106%;text-align: left;">Ehlers-Danlos vascular type (type III)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Alport (type IV mutation)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Goodpasture (type IV Abs)</p></li></ul><ul id="l64"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Not Gly-X-Y structure</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Not triple-helical</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Exhibits desmosine cross-linking</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 5pt;text-indent: -18pt;line-height: 106%;text-align: left;">Stabilized by fibrillin (fibrillin forms sheath around elastin)</p></li><li><p class="s4" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Contains lots of LYSINE (on NBME)</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-top: 9pt;padding-left: 94pt;text-indent: -18pt;line-height: 191%;text-align: left;">28M + tall + flat feet + mitral valve prolapse + headaches; Dx? <span class="s2">➔ </span>answer = MEN 2B, not Marfan syndrome.</p></li><li><p style="padding-top: 2pt;padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">3M + atrial myxoma + hyperpigmentation around the lips + hyperthyroidism; what’s the most likely diagnosis? <span class="s2">➔ </span>answer = Carney complex.</p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:451pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s3" style="padding-left: 102pt;padding-right: 101pt;text-indent: 0pt;line-height: 13pt;text-align: center;">Multiple endocrine neoplasia syndromes</p></td></tr><tr style="height:13pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;line-height: 10pt;text-align: center;">Condition</p></td><td style="width:331pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 105pt;padding-right: 104pt;text-indent: 0pt;line-height: 10pt;text-align: center;">HY constellation of findings</p></td></tr><tr style="height:49pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">MEN 1</p></td><td style="width:331pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:49pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">MEN 2A</p></td><td style="width:331pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:61pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">MEN 2B</p></td><td style="width:331pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:49pt"><td style="width:120pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">Carney complex</p></td><td style="width:331pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l65"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 10pt;text-align: left;">Pituitary tumor (e.g., prolactinoma)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Parathyroid adenoma / diffuse hyperplasia</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Pancreatic tumor (e.g., gastrinoma)</p></li><li><p class="s7" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">MEN1 <span class="s5">gene; AD; chromosome 11</span></p></li></ul><ul id="l66"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 10pt;text-align: left;">Medullary thyroid carcinoma</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Pheochromocytoma</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Parathyroid adenoma / diffuse hyperplasia</p></li><li><p class="s7" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">RET <span class="s5">oncogene; AD; chromosome 10</span></p></li></ul><ul id="l67"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 10pt;text-align: left;">Medullary thyroid carcinoma</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Pheochromocytoma</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Marfanoid body habitus</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Mucosal neuromas</p></li><li><p class="s7" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">RET <span class="s5">oncogene; AD; chromosome 10</span></p></li></ul><ul id="l68"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 10pt;text-align: left;">Atrial myxoma <i>in a kid</i></p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Perioral melanosis (hyperpigmentation around the lips)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Endocrine hypersecretion (e.g., Cushing, hyperthyroidism)</p></li><li><p class="s7" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">PRKAR1 <span class="s5">mutation; fuses with </span>RET <span class="s5">via gene rearrangement</span></p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><h2 style="padding-top: 9pt;padding-left: 94pt;text-indent: -18pt;text-align: left;"><a name="a4">Sugar disorders</a><span class="p">:</span></h2><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l69"><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 198%;text-align: left;">Both galactose and fructose disorder vignettes may carry the descriptor of “reducing sugars” in the urine. Galactose disorders are detected by heel prick test at birth.</p></li><li><p style="padding-top: 4pt;padding-left: 130pt;text-indent: -18pt;line-height: 198%;text-align: left;">Galactose disorders surface earlier than fructose disorders because of ingestion of milk (lactose = galactose + glucose).</p></li><li><p style="padding-top: 2pt;padding-bottom: 3pt;padding-left: 130pt;text-indent: -18pt;line-height: 198%;text-align: left;">Fructose disorders don’t surface until infant commences fruit, juice, honey, and/or table sugar (sucrose = fructose + glucose).</p></li></ul><p style="padding-left: 58pt;text-indent: 0pt;text-align: left;"><span><img width="616" height="200" alt="image" src="Image_025.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 61pt;text-indent: 0pt;text-align: left;"><span><img width="626" height="140" alt="image" src="Image_026.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:450pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="3"><p class="s18" style="padding-left: 150pt;padding-right: 150pt;text-indent: 0pt;line-height: 13pt;text-align: center;">Sugar disorders for USMLE</p></td></tr><tr style="height:16pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-top: 1pt;padding-left: 20pt;padding-right: 19pt;text-indent: 0pt;text-align: center;">Condition</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-top: 1pt;padding-left: 10pt;padding-right: 10pt;text-indent: 0pt;text-align: center;">Enzyme deficiency</p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-top: 1pt;padding-left: 11pt;padding-right: 10pt;text-indent: 0pt;text-align: center;">HY point(s)</p></td></tr><tr style="height:86pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 20pt;padding-right: 19pt;text-indent: 0pt;text-align: center;">Galactokinase deficiency</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 10pt;padding-right: 10pt;text-indent: 0pt;text-align: center;">Galactokinase</p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;text-align: justify;">glucose); screened via heel-prick test</p></td></tr><tr style="height:98pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 20pt;padding-right: 19pt;text-indent: 0pt;text-align: center;">Classic galactosemia</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 15pt;padding-right: 14pt;text-indent: 0pt;text-align: center;">galactose-1- phosphate uridyl transferase</p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">glucose); screened via heel-prick test</p></td></tr><tr style="height:37pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 20pt;padding-right: 19pt;text-indent: 0pt;text-align: center;">Essential fructosuria</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 10pt;padding-right: 10pt;text-indent: 0pt;text-align: center;">Fructokinase</p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l70"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: justify;">From birth (milk lactose <span class="s8">➔ </span>galactose +</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: justify;">Cataracts in neonate</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 7pt;text-indent: -18pt;line-height: 106%;text-align: justify;">Aldose reductase converts galactose <span class="s8">➔ </span>galactitol, which has tt osmotic pull in lens</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: justify;">Milder than classic galactosemia</p></li></ul><ul id="l71"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;">From birth (milk lactose <span class="s8">➔ </span>galactose +</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Cataracts in neonate</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Hepatomegaly, jaundice, hypoglycemia</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Associated with <i>E. coli </i>sepsis</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 38pt;text-indent: -18pt;line-height: 106%;text-align: left;">Trapped G1P in liver sequesters phosphate</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Worse than GK deficiency</p></li></ul><ul id="l72"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Benign condition</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 11pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Mere presence of “reducing sugars” in the urine</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:37pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 106%;text-align: left;">-  Negative glucose oxidase urine test (indicating reducing sugars are not</p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">glucose)</p></td></tr><tr style="height:61pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 10pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">Hereditary fructose intolerance</p></td><td style="width:99pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 10pt;padding-left: 28pt;text-indent: 0pt;text-align: left;">Aldolase B</p></td><td style="width:209pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l73"><li><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;text-align: left;">Begins with dietary introduction of juice, fruit, honey, and table sugar</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Hepatomegaly, jaundice, hypoglycemia</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 40pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Trapped F1P in liver sequesters phosphate</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 206%;text-align: justify;">Researcher is looking at a compound that is taken up by cells + no energy is required for uptake + the compound is not concentrated in the cell; Q asks, which mechanism best describes this mechanism of transport? <span class="s2">➔ </span>answer = carrier-mediated diffusion (facilitated diffusion/transport).</p><ul id="l74"><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Passive transport (no energy required):</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l75"><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">Simple diffusion <span class="s2">➔ </span>molecules moving freely down concentration gradient without any type of transporter (e.g., nitric oxide moving into cell).</p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">Facilitated diffusion <span class="s2">➔ </span>molecules moving down concentration gradient with the help of a transport protein (e.g., GLUT transporters for monosaccharides).</p></li></ul></li><li><p style="padding-top: 2pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">Active transport (energy required):</p><ul id="l76"><li><p style="padding-top: 10pt;padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">Primary active transport <span class="s2">➔ </span>ATP is used directly to move molecules (e.g., Na<span class="s15">+</span>/K<span class="s15">+</span><span class="s16"> </span>ATPase pumps – i.e., Na<span class="s15">+</span><span class="s16"> </span>and K<span class="s15">+</span><span class="s16"> </span>are directly transported via the use of ATP).</p></li><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;line-height: 200%;text-align: left;">Secondary active transport <span class="s2">➔ </span>ATP is used to indirectly transport molecules elsewhere (e.g., ENaC on apical membrane of renal cortical collecting duct – i.e., Na<span class="s15">+</span><span class="s16"> </span>moves down concentration gradient via ENaC from the urine into the cell, but this is</p><p style="padding-top: 1pt;padding-left: 166pt;text-indent: 0pt;line-height: 211%;text-align: left;">only possible because a favorable high-to-low gradient is first established via a Na<span class="s15">+</span>/K<span class="s15">+</span><span class="s16"> </span>ATPase pump on the basolateral membrane, as stimulated by aldosterone).</p></li></ul></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 208%;text-align: left;">35F + recurrent bronchitis and sinusitis throughout life + Hx of ectopic pregnancy + cardiac exam shows point of maximal impulse at the 4<span class="s15">th</span><span class="s16"> </span>intercostal space right midclavicular line + biopsy of nasal polyp taken; Q asks, which structure is most likely to be absent on electron microscopy of the biopsy specimen? <span class="s2">➔ </span>answer = dynein arms; Dx is primary ciliary dyskinesia (Kartagener syndrome); dynein</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 9pt;text-align: left;">arms are required for function of cilia, which normally line the pseudostratified columnar epithelium</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 196%;text-align: left;">of the respiratory tree <span class="s2">➔ </span>decreased function of cilia <span class="s2">➔ </span>increased respiratory tract infections; Kartagener is associated with situs inversus / dextrocardia; t ectopic pregnancies in females (cilia</p><p style="padding-top: 5pt;padding-left: 94pt;text-indent: 0pt;line-height: 214%;text-align: left;">normally line Fallopian tubes) and --1 sperm motility in males (infertility); a cilium comprises a 9x2 circumferential pattern of microtubules on 2D-cross-section (i.e., a cilium is much larger than microtubules); should be noted that whilst sperm demonstrate --1 motility in Kartagener, there are <i>absent </i>sperm in cystic fibrosis due to CBAVD (congenital bilateral absence of vas deferens) – i.e., recurrent sinopulmonary infections + absent sperm = CF; whereas recurrent sinopulmonary infections</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 11pt;text-align: left;">+ immotile sperm = Kartagener. Cross-section of cilium showing 9x2 microtubules circumferentially:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 242pt;text-indent: 0pt;text-align: left;"><span><img width="157" height="147" alt="image" src="Image_027.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">6M + 3<span class="s15">rd</span><span class="s16"> </span>percentile for weight and height + failed to pass meconium at birth; which of the following molecular combinations best describes the defective channel inherent to this patient’ disease? <span class="s2">➔ </span>answer = cAMP and ATP; diagnosis is cystic fibrosis (AR; chromosome 7); CFTR is a cAMP-mediated, ATP-gated chloride channel; the defective channel is retained within the RER of the cytosol (i.e., it is</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;"><span class="s17">not </span>found on the cell membrane); sweat chloride test demonstrating &gt;60 mEq/L is <i>more accurate </i>than genotyping due to tt allelic heterogeneity (i.e., many diseased alleles can produce the CF phenotype; even detailed genetic screening panels only detect upward of 90-96% of the most common mutations); i1F508 (deletion of phenylalanine at position 508) is most common CF mutation; patients have negative nasal transepithelial potential difference (one type of diagnostic test); <i>Staph aureus </i>exceeds <i>Pseudomonas </i>for most common cause of CF pneumonia in first decade of life; after first decade, <i>Pseudomonas </i>exceeds <i>Staph</i>; phenotypically normal sibling of patient with CF has 2/3 chance of being a carrier (i.e., we can eliminate the aa on the Punnett square because the unaffected sibling clearly doesn’t have the disease, so 2Aa / 2Aa + 1AA); dornase-alfa (correct, not alpha) is a nucleotidase that can help clear mucous from respiratory tree; <i>N</i>-acetylcysteine has -SH groups that can help breakdown mucous; guaifenesin softens mucous; ivacaftor is CFTR modulator that can help re-fold protein into functional form.</p></li><li><p style="padding-left: 94pt;text-indent: -88pt;text-align: left;">24F + autosomal recessive condition + low serum vitamin D + Hx of two episodes of <i>Pseudomonas</i></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;text-align: left;">pneumonia; what is most likely to occur on a cellular level in this patient’s pancreatic ducts? <span class="s2">➔</span></p><p style="padding-top: 3pt;padding-left: 94pt;text-indent: 0pt;line-height: 182%;text-align: left;">answer = “upregulation of ENaC”; Dx is cystic fibrosis; CFTR channel is defective <span class="s2">➔ </span>Cl<span class="s15">-</span><span class="s16"> </span>cannot be secreted out of pancreatic ducts into the lumen <span class="s2">➔ </span>more Cl<span class="s15">-</span><span class="s16"> </span>is retained in the cell <span class="s2">➔ </span>more Na<span class="s15">+</span><span class="s16"> </span>moves from lumen into the cell to balance charge via ENaC <span class="s2">➔ </span>water follows Na+ <span class="s2">➔ </span>secretions within pancreatic duct lumen inspissate (i.e., desiccate within a lumen) <span class="s2">➔ </span>exocrine pancreas malsecretion <span class="s2">➔ </span>impaired absorption of fat-soluble vitamins and macronutrients <span class="s2">➔ </span>failure to thrive.</p><ul id="l77"><li><p style="padding-top: 1pt;padding-left: 130pt;text-indent: -18pt;line-height: 194%;text-align: left;">Should be noted that chloride moves the opposite direction in sweat glands – i.e., rather than CTFR functioning to secrete Cl<span class="s15">-</span>, it reabsorbs it, hence our positive sweat chloride test.</p></li></ul></li><li><p style="padding-top: 3pt;padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">17F + taking OCPs + taking isotretinoin for acne past two years + has headache + is vegan; which vitamin is most likely responsible for her headache <span class="s2">➔ </span>answer = vitamin A <span class="s2">➔ </span>isotretinoin (high-dose vitamin A) and OCPs both can cause pseudotumor cerebri (increased intracranial pressure); veganism can cause B12 deficiency, not excess, nor does that relate to headaches.</p></li><li><p style="padding-bottom: 2pt;padding-left: 94pt;text-indent: -18pt;line-height: 187%;text-align: left;">Investigator is looking at enzyme that is a giant complex; which of the following is most likely? <span class="s2">➔ </span>answer = pyruvate dehydrogenase (converts pyruvate <span class="s2">➔ </span>acetyl-CoA of TCA cycle); described as giant complex of vitamins B1, B2, B3, B5, and lipoic acid.</p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:451pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s3" style="padding-left: 102pt;padding-right: 101pt;text-indent: 0pt;line-height: 13pt;text-align: center;">HY vitamins and minerals for USMLE</p></td></tr><tr style="height:13pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Nutrient</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 40pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY points</p></td></tr><tr style="height:221pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 15pt;padding-right: 14pt;text-indent: 0pt;line-height: 106%;text-align: center;">Vitamin A (retinol, retinal, retinoic acid)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:98pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 20pt;text-indent: -1pt;text-align: left;">Vitamin B1 (thiamine)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l78"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Transcription factor; binds to retinoic acid receptor</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Topical tretinoin is first-line for acne (shuts off sebum production)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 23pt;text-indent: -18pt;line-height: 106%;text-align: left;">Oral isotretinoin (ultra-high-concentration vitamin A) is last-line (and most effective) for acne; high-dose vitamin A is teratogenic; must do beta-hCG before starting isotretinoin</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 9pt;text-indent: -18pt;line-height: 106%;text-align: left;">If USMLE asks what kind of teratogenicity is associated with vitamin A, choose cleft lip/palate</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 23pt;text-indent: -18pt;line-height: 106%;text-align: left;">Topical tretinoin is not teratogenic but causes desquamation (peeling) and photosensitivity (asked on 2CK FM shelf)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Vitamin A is required for night vision, skin, and immune function</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Deficiency causes nyctalopia, squamous metaplasia, immunodeficiency</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 38pt;text-indent: -18pt;line-height: 106%;text-align: left;">Deficiency rare because Vitamin A is fat-soluble and also stored in high amounts in the liver in Ito cells</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Fat-soluble vitamins are A, D, E, K (All Dogs Eat Kittens)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Deficiency can be caused by malabsorptive disorders such as CF, Celiac, Crohn</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 7pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Excess causes cerebral edema with pseudotumor cerebri (t ICP, papilledema, confusion), teratogenicity, hepatotoxicity, and dyslipidemia; ursine (bear) liver is known cause of toxicity</p></li></ul><ul id="l79"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Used for dehydrogenase reactions</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Four thiamine-dependent enzymes for USMLE are:</p><ol id="l80"><li><p class="s5" style="padding-left: 51pt;text-indent: -10pt;line-height: 13pt;text-align: left;">Pyruvate dehydrogenase (pyruvate <span class="s8">➔ </span>acetyl-CoA)</p></li><li><p class="s5" style="padding-left: 51pt;text-indent: -10pt;line-height: 13pt;text-align: left;">Alpha-ketoglutarate dehydrogenase (alpha-KG <span class="s8">➔ </span>succinyl-CoA in TCA cycle)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 35pt;text-indent: 0pt;line-height: 106%;text-align: left;">Branched-chain ketoacid dehydrogenase (Maple syrup urine disease; inability to metabolize leucine, isoleucine, valine)</p></li><li><p class="s5" style="padding-left: 51pt;text-indent: -10pt;text-align: left;">Transketolase (produced in HMP shunt)</p></li></ol></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Deficiency (classic in alcoholics) causes:</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:123pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 77pt;text-indent: 0pt;line-height: 11pt;text-align: left;">cardiomyopathy</p></td></tr><tr style="height:61pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 19pt;padding-right: 18pt;text-indent: 0pt;line-height: 106%;text-align: left;">Vitamin B2 (riboflavin)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:221pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 26pt;text-indent: -7pt;line-height: 106%;text-align: left;">Vitamin B3 (niacin)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">answer = niacin (since can cause gout)</p></td></tr><tr style="height:37pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 10pt;padding-right: 10pt;text-indent: 0pt;line-height: 106%;text-align: center;">Vitamin B5 (pantothenate,</p><p class="s5" style="padding-left: 5pt;padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: center;">pantothenic acid)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:185pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 17pt;padding-right: 16pt;text-indent: 0pt;line-height: 106%;text-align: center;">Vitamin B6 (pyridoxine, pyridoxal phosphate)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">neuropathy +/- seizures</p></td></tr><tr style="height:62pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 26pt;text-indent: -7pt;line-height: 106%;text-align: left;">Vitamin B7 (biotin)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l81"><li><p class="s5" style="padding-left: 77pt;padding-right: 13pt;text-indent: -18pt;text-align: left;">Wernicke-Korsakoff syndrome (area of brain affected is mammillary bodies)</p></li><li><p class="s26" style="padding-left: 77pt;padding-right: 15pt;text-indent: -18pt;text-align: left;"><span class="s5">Acronym for Wernicke encephalopathy </span><span class="s8">➔ </span>A COW <span class="s8">➔ </span>A<span class="s5">taxia, </span>C<span class="s5">onfusion, </span>O<span class="s5">phthalmoplegia, </span>W<span class="s5">ernicke; B1 given with glucose in emergency setting to unconscious patients; if Q asks why B1 should be given to alcoholic patient, answer = prevention of anterograde amnesia</span></p></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Korsakoff psychosis <span class="s8">➔ </span>confabulation due to retrograde amnesia</p></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Dry and wet beriberi: dry = neuropathy; wet = dilated</p></li></ul><ul id="l82"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Used as a cofactor in FAD/FMN reactions</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Required for succinate <span class="s8">➔ </span>fumarate in TCA cycle, where FAD <span class="s8">➔ </span>FADH2</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">B2 and B6 used as cofactors in B3 synthesis</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 31pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Deficiency causes ariboflavinosis (angular cheilitis; although non-specific finding)</p></li></ul><ul id="l83"><li><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;line-height: 106%;text-align: left;">Used for NAD+/NADH reactions; Q might give you patient with B3 deficiency and then have you select “adenine” as the answer; B3 is part of a cofactor that contains adenine</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">HY cardiovascular effects: tt HDL; --1 VLDL export by the liver</p></li><li><p class="s5" style="padding-top: 1pt;padding-left: 41pt;padding-right: 30pt;text-indent: -18pt;line-height: 106%;text-align: left;">Tryptophan is precursor to niacin synthesis; Hartnup disease (--1 ability to reabsorb tryptophan in PCT of kidney) leads to niacin deficiency</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 37pt;text-indent: -18pt;line-height: 106%;text-align: left;">Tryptophan also precursor to serotonin; carcinoid syndrome consumes tryptophan, leading to niacin deficiency in some cases</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 19pt;text-indent: -18pt;line-height: 106%;text-align: left;">Deficiency causes pellagra (dementia, dermatitis, diarrhea); can present as delirium (biggest risk factor for delirium is underlying dementia); dermatitis will be either Casal necklace, hyperpigmentation of forearms, or blistering</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 14pt;text-indent: -18pt;text-align: left;">Excess causes hyperinsulinemia (insulin resistance and diabetes), hyperuricemia (gout), and flushing (due to prostaglandin, <span class="s13">not </span>histamine) <span class="s8">➔ </span>aspirin/NSAID can be used to prevent/mitigate flushing, so makes sense that prostaglandin, not histamine, is the cause</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;text-align: left;">Q will tell you guy has big cardiovascular history and podagra (gout of big toe; don’t confuse with pellagra) and then ask which agent is contraindicated <span class="s8">➔</span></p></li></ul><ul id="l84"><li><p class="s5" style="padding-top: 6pt;padding-left: 41pt;text-indent: -18pt;text-align: left;">Precursor to coenzyme-A (transferred to pyruvate to make acetyl-CoA)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Deficiency causes burning feet syndrome</p></li></ul><ul id="l85"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Used for decarboxylase reactions:</p><ul id="l86"><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 13pt;text-align: left;">L-Dopa, via L-Dopa decarboxylase <span class="s8">➔ </span>dopamine</p></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Glutamic acid, via glutamic acid decarboxylase <span class="s8">➔ </span>GABA</p></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Histidine, via histidine decarboxylase <span class="s8">➔ </span>histamine</p></li></ul></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Transaminase reactions:</p><ul id="l87"><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Pyruvate + glutamate, via B6 and ALT <span class="s8">➔ </span>a-KG + alanine</p></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Oxaloacetate + glutamate, via B6 and AST <span class="s8">➔ </span>a-KG + aspartate</p></li></ul></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">First step in heme synthesis:</p><ul id="l88"><li><p class="s21" style="padding-left: 77pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Succinyl-CoA + glycine, via B6 and <span class="s27">8</span><span class="s28">-ALA</span> synthase <span class="s29">➔ </span><span class="s27">8</span><span class="s28">-ALA</span></p></li><li><p class="s5" style="padding-left: 77pt;padding-right: 18pt;text-indent: -18pt;text-align: left;">This first step in heme synthesis sounds pedantic but it’s HY and all over the Step 1 NBMEs</p></li></ul></li><li><p class="s5" style="padding-left: 41pt;padding-right: 27pt;text-indent: -18pt;line-height: 106%;text-align: left;">Used to synthesize cysteine from homocysteine (B6 can be given to some patients with homocysteinuria)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;"><span class="s21">Deficiency caused by isoniazid </span>(patients with TB) <span class="s8">➔ </span>presents as peripheral</p></li></ul><ul id="l89"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Used for carboxylase reactions:</p><ul id="l90"><li><p class="s5" style="padding-left: 77pt;padding-right: 30pt;text-indent: -18pt;text-align: left;">Pyruvate carboxylase (pyruvate <span class="s8">➔ </span>oxaloacetate [OAA]); this is a gluconeogenic enzyme</p><ul id="l91"><li><p class="s5" style="padding-left: 113pt;padding-right: 25pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Final step of glycolysis: PEP <span class="s8">➔ </span>pyruvate (irreversible, via pyruvate kinase)</p></li></ul></li></ul></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:220pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 113pt;text-indent: 0pt;line-height: 11pt;text-align: left;">goes to OAA via pyruvate carboxylase</p><p class="s5" style="padding-left: 113pt;text-indent: 0pt;text-align: left;">converted to succinyl-CoA in the TCA cycle using B12</p><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-  Deficiency caused by eating raw egg whites (contain avidin, which bind B7)</p></td></tr><tr style="height:221pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 19pt;padding-right: 18pt;text-indent: 0pt;line-height: 106%;text-align: center;">Vitamin B9 (folate, folic acid)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">(dTMP) + THF; <span class="s30">5-fluorouracil (5-FU) </span>is a thymidylate synthase inhibitor</p><p class="s31" style="padding-left: 77pt;padding-right: 7pt;text-indent: -18pt;text-align: left;">o <span class="s5">Methionine is then phosphorylated by ATP to make S-adenosyl- methionine (SAM), which is a universal methyl donor used in numerous nucleic acid, protein, and lipid reactions</span></p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">acid are t</p></td></tr><tr style="height:232pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 7pt;padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: left;">Vitamin B12 (cyanocobalamin)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;text-align: left;">methionine + THF); methionine is an essential amino acid</p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">tracts, dorsal columns, and spinocerebellar tracts (<i>spinothalamic not involved</i>)</p></td></tr></table><ul id="l92"><li><p class="s5" style="padding-left: 113pt;text-indent: -18pt;line-height: 12pt;text-align: left;">In order to go backwards (pyruvate <span class="s8">➔ </span>PEP), pyruvate first</p></li><li><p class="s5" style="padding-left: 113pt;text-indent: -18pt;line-height: 13pt;text-align: left;">OAA <span class="s8">➔ </span>PEP, via PEP carboxykinase</p></li><li><p class="s5" style="padding-left: 113pt;text-indent: -18pt;line-height: 12pt;text-align: left;">PEP can then go back to glucose</p></li></ul><ul id="l93"><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Acetyl-CoA carboxylase (Acetyl-CoA <span class="s8">➔ </span>malonyl-CoA)</p><ul id="l94"><li><p class="s5" style="padding-left: 113pt;padding-right: 13pt;text-indent: -18pt;line-height: 12pt;text-align: left;">First step in fatty acid synthesis, as malonyl-CoA undergoes further reactions for FA assembly</p></li><li><p class="s5" style="padding-left: 113pt;padding-right: 9pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Malonyl-CoA also inhibits fatty acid breakdown by inhibiting the carnitine shuttle (ordinarily enables FAs to move from the cytosol to mitochondria for beta-oxidation)</p></li></ul></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Propionyl-CoA carboxylase (propionyl-CoA <span class="s8">➔ </span>methylmalonyl-CoA)</p><ul id="l95"><li><p class="s5" style="padding-left: 113pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Odd-chain fatty acid breakdown</p></li><li><p class="s5" style="padding-left: 113pt;padding-right: 15pt;text-indent: -18pt;text-align: left;">FAs are broken down into 2-carbon acetyl-CoA units, but if the FA is odd-chain, a terminal 3-carbon unit is liberated called propionyl-CoA</p></li><li><p class="s5" style="padding-left: 113pt;text-indent: -18pt;line-height: 12pt;text-align: left;">After conversion to methylmalonyl-CoA, the latter is</p></li></ul></li></ul><ul id="l96"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Used in an array of complex reactions with B12</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 30pt;text-indent: -18pt;line-height: 106%;text-align: left;">Folate assumes numerous forms, including THF, 5-methyl-THF, and 5,10- methylene-THF</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -40pt;line-height: 12pt;text-align: left;">Uracil (dUMP) + 5,10-methylene-THF, via thymidylate synthase <span class="s8">➔ </span>thymine</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 67pt;text-indent: -41pt;line-height: 13pt;text-align: left;">Homocysteine + 5-methyl-THF + B12 <span class="s8">➔ </span>methionine + THF</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">B9 found in dark green, leafy vegetables</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Deficiency leads to megaloblastic anemia and hypersegmented neutrophils</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Deficiency causes neural tube defects (critical during first 3-4 weeks gestation)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 25pt;text-indent: -18pt;line-height: 106%;text-align: left;">Antiepileptics (i.e., valproic acid, phenytoin, carbamazepine) can cause B9 deficiency; Q will give you an image of a hypersegmented neutrophil in someone on phenytoin, and you need to know it’s B9, not B12, deficiency</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 5pt;text-indent: -18pt;line-height: 106%;text-align: left;">Deficiency causes: t homocysteine and <span class="s32">no change </span>methylmalonyl-CoA (or methylmalonic acid); in B12 deficiency, <span class="s32">both </span>homocysteine and methylmalonic</p></li></ul><ul id="l97"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Used in an array of complex reactions with B9</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Required by methionine synthase (homocysteine + 5-methyl-THF <span class="s8">➔</span></p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Regenerates the THF form of B9:</p><ul id="l98"><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Homocysteine + 5-methyl-THF + B12 <span class="s8">➔ </span>methionine + THF</p></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Methionine + ATP <span class="s8">➔ </span>S-adenosyl methionine (SAM)</p></li><li><p class="s5" style="padding-left: 77pt;padding-right: 22pt;text-indent: -18pt;text-align: left;">SAM is a universal methyl-group donor, used in many nucleic acid reactions</p></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 12pt;text-align: left;">After SAM transfers a methyl group, homocysteine is regenerated</p></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 11pt;text-align: left;">So in summary:</p></li></ul></li></ul><ol id="l99"><li><p class="s5" style="padding-left: 69pt;text-indent: -10pt;line-height: 12pt;text-align: left;">Homocysteine + 5-methyl-THF, via B12 <span class="s8">➔ </span>methionine + THF</p></li><li><p class="s5" style="padding-left: 69pt;text-indent: -10pt;line-height: 12pt;text-align: left;">Methionine + ATP <span class="s8">➔ </span>SAM</p></li><li><p class="s5" style="padding-left: 69pt;text-indent: -10pt;line-height: 12pt;text-align: left;">SAM donates -CH3 elsewhere <span class="s8">➔ </span>homocysteine</p></li></ol><ul id="l100"><li><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;text-align: left;">Required by methylmalonyl-CoA mutase (methylmalonyl-CoA <span class="s8">➔ </span>succinyl- CoA); this occurs during odd-chain FA breakdown</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 14pt;text-indent: -18pt;text-align: left;">Deficiency causes megaloblastic anemia and hypersegmented neutrophils (same as with B9), however unique to B12 deficiency is a type of neuropathy called subacute combined degeneration <span class="s8">➔ </span>demyelination of corticospinal</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:160pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s31" style="padding-left: 77pt;padding-right: 41pt;text-indent: -18pt;text-align: left;">o <span class="s5">Subacute combined degeneration is caused by the buildup of methylmalonyl-CoA, which is toxic to myelin</span></p></td></tr><tr style="height:99pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 12pt;text-indent: 9pt;line-height: 106%;text-align: left;">Vitamin C (ascorbic acid)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr><tr style="height:347pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 21pt;text-indent: 0pt;text-align: left;">Vitamin D</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 7pt;text-indent: 0pt;line-height: 106%;text-align: left;">tells you someone doesn’t get sunlight, the answer is deficiency of cholecalciferol (<i>those who don’t get sunlight still make 7-dehydrocholesterol</i>)</p></td></tr><tr style="height:74pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 15pt;padding-right: 14pt;text-indent: 0pt;line-height: 106%;text-align: center;">Vitamin E (tocopherol, tocotrienol)</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">won’t be listed, and you choose E instead.</p></td></tr></table><ul id="l101"><li><p class="s5" style="padding-top: 1pt;padding-left: 41pt;padding-right: 60pt;text-indent: -18pt;line-height: 111%;text-align: left;">Deficiency causes: t homocysteine <span class="s32">and </span>t methylmalonyl-CoA (or methylmalonic acid); in B9 deficiency, <span class="s32">only </span>homocysteine is t</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Deficiency caused by:</p><ul id="l102"><li><p class="s5" style="padding-left: 77pt;padding-right: 5pt;text-indent: -18pt;text-align: left;">Loss of parietal cells (i.e., pernicious anemia, gastric bypass surgery, chronic gastritis); parietal cells make intrinsic factor, which is required for absorption of B12 at the terminal ileum</p></li><li><p class="s5" style="padding-left: 77pt;padding-right: 35pt;text-indent: -18pt;text-align: left;">Terminal ileum resection, or absorptive disorders affecting the terminal ileum, such as Crohn disease</p></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Veganism or strict vegetarianism</p></li><li><p class="s7" style="padding-left: 77pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Diphyllobothrium latum <span class="s5">(fish tapeworm) infection</span></p></li><li><p class="s5" style="padding-left: 77pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Schilling test can be used to ascertain etiology of deficiency</p></li></ul></li></ul><ul id="l103"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Used in hydroxylase reactions</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Collagen synthesis (hydroxylation of proline and lysine residues)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Norepinephrine synthesis (dopamine <span class="s8">➔ </span>NE, via dopamine �-hydroxylase)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Plays a role in immune function</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Required for iron absorption in duodenum (vitamin C ferrireductase)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 25pt;text-indent: -18pt;text-align: left;">Deficiency causes scurvy <span class="s8">➔ </span>bleeding gums, perifollicular hemorrhages, ill- appearing patient</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Excess causes calcium oxalate stones</p></li></ul><ul id="l104"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Required for calcium homeostasis and bone calcification</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 33pt;text-indent: -18pt;line-height: 106%;text-align: left;">Synthesis starts in stratum basale of epidermis as 7-dehydrocholesterol; USMLE will specifically ask you which layer, so know stratum basale</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;">7-dehydrocholesterol, via UVB radiation <span class="s8">➔ </span>cholecalciferol; if the USMLE Q</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;line-height: 109%;text-align: left;">Cholecalciferol goes to the liver, where it’s hydroxylated to make 25-OH-D3 (calcidiol); if the Q gives you an alcoholic, then 25-OH-D3 will be --1, where the answer is “decreased hepatic hydroxylation”</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 26pt;text-indent: -18pt;line-height: 106%;text-align: left;">25-OH-D3 then goes to the PCT of the kidney, where PTH upregulates 1a- hydroxylase to convert 25-OH-D3 into 1,25-(OH)<span class="s22">2</span>-D3 (calcitriol)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 34pt;text-indent: -18pt;line-height: 106%;text-align: left;">1,25-(OH)<span class="s22">2</span>-D3 then goes to the small bowel where it causes Ca and PO<span class="s22">4</span><span class="s23"> </span>absorption</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 9pt;text-indent: -18pt;text-align: left;">1,25-(OH)<span class="s22">2</span>-D3 also goes to bone where it converts unmineralized osteoid into mineralized hydroxyapatite</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Vitamin D deficiency causes rickets (children) and osteomalacia (adults)</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Deficiency can be caused by malabsorptive disorders such as CF, Celiac, Crohn</p></li><li><p class="s5" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;text-align: left;">For deficiency, choose --1 Ca, --1 PO<span class="s22">4</span>, t PTH (goes up to compensate for --1 Ca)</p></li><li><p class="s5" style="padding-top: 1pt;padding-left: 41pt;padding-right: 20pt;text-indent: -18pt;line-height: 111%;text-align: left;">Mechanism for --1 Ca in renal failure is a combination of 1) not being able to reabsorb Ca in the late-DCT under the action of PTH, and 2) --1 PCT 1a- hydroxylation means --1 small bowel absorption of Ca</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 21pt;text-indent: -18pt;text-align: left;">Hypervitaminosis D (vitamin D excess) due to granulomatous diseases; on USMLE this is always sarcoidosis <span class="s8">➔ </span>epithelioid macrophages within non- caseating granulomas produce 1a-hydroxylase without the need for PTH; calcitriol increases <span class="s8">➔ </span>t small bowel absorption of Ca <span class="s8">➔ </span><b>PTH is suppressed</b></p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">For high vitamin D (sarcoidosis), select t Ca, t PO<span class="s22">4</span>, --1PTH.</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 9pt;text-indent: -18pt;line-height: 12pt;text-align: left;">William syndrome <span class="s8">➔ </span>AD, chromosome 7, elfin-like facies, supravalvular aortic stenosis, hypercalcemia secondary to increased vitamin D sensitivity</p></li></ul><ul id="l105"><li><p class="s5" style="padding-left: 41pt;padding-right: 32pt;text-indent: -18pt;line-height: 106%;text-align: left;">Free-radical scavenger; incorporates into cell membranes and donates a hydrogen atom to free radicals</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 15pt;text-indent: -18pt;line-height: 106%;text-align: left;">Deficiency is rare but associated with neuropathy similar to the subacute combined degeneration seen in B12 deficiency; USMLE will give a Q where a patient has neuropathy and they ask for the vitamin deficiency, where B12</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:25pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;">-  Excess can antagonize the effects of aspirin, warfarin, and various</p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">chemotherapeutic agents</p></td></tr><tr style="height:159pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 15pt;padding-right: 14pt;text-indent: 0pt;text-align: center;">Vitamin K</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-right: 22pt;text-indent: 0pt;text-align: right;">factors II, VII, IX, and X, as well as anti-clotting proteins C and S, hepatically</p></td></tr><tr style="height:111pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 8pt;padding-left: 15pt;padding-right: 14pt;text-indent: 0pt;text-align: center;">Copper</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 16pt;text-indent: 0pt;line-height: 106%;text-align: left;">copper into bile; leads to t copper in urine + --1 serum ceruloplasmin; causes hemolytic anemia, cirrhosis, Parkinsonism (Cu deposition in basal ganglia), Kayser-Fleischer rings (deposition in Descemet membrane of cornea); Tx is penicillamine (copper chelator)</p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">causes “wiry” or “springy” hair</p></td></tr><tr style="height:110pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 7pt;padding-left: 15pt;padding-right: 14pt;text-indent: 0pt;text-align: center;">Iron</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(secondary hemochromatosis due to chronic blood transfusions)</p></td></tr><tr style="height:13pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 15pt;padding-right: 14pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Selenium</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s34" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><span style=" color: #000;">-  Essential cofactor for glutathione peroxidase (</span>2G-SH + H<span class="s35">2</span>O<span class="s35">2</span><span class="s36"> </span>→ GS–SG + 2H<span class="s35">2</span>O)</p></td></tr><tr style="height:61pt"><td style="width:83pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 15pt;padding-right: 14pt;text-indent: 0pt;text-align: center;">Zinc</p></td><td style="width:368pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l106"><li><p class="s5" style="padding-left: 41pt;padding-right: 21pt;text-indent: -41pt;line-height: 12pt;text-align: right;">Cofactor for the enzyme gamma-glutamyl-carboxylase <span class="s8">➔ </span>activates clotting</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 6pt;text-indent: -18pt;line-height: 106%;text-align: left;">Do not confuse gamma-glutamyl-carboxylase with vitamin K epoxide reductase; the latter is inhibited by warfarin, but vitamin K is a cofactor for the former; vitamin K epoxide reductase merely recycles vitamin K to its active form</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Deficiency will present in two ways on USMLE:</p><ul id="l107"><li><p class="s5" style="padding-left: 77pt;padding-right: 8pt;text-indent: -18pt;text-align: left;">Neonate with bleeding from umbilical stump (sterile bowl in neonate has not yet synthesized vitamin K; neonate needs Vit K injection)</p></li><li><p class="s5" style="padding-top: 1pt;padding-left: 77pt;padding-right: 37pt;text-indent: -18pt;text-align: left;">Older patient on broad-spectrum Abs for 6+ weeks, leading to obliteration of gut flora</p></li></ul></li><li><p class="s5" style="padding-left: 41pt;padding-right: 9pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Vitamin K is the slow reversal agent for warfarin (if patient is actively bleeding or requires surgery, give fresh frozen plasma instead)</p></li></ul><ul id="l108"><li><p class="s5" style="padding-left: 41pt;padding-right: 31pt;text-indent: -18pt;line-height: 106%;text-align: left;">Essential cofactor for lysyl oxidase, which catalyzes crosslinking of newly synthesized collagen and elastin</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Excess seen with Wilson disease <span class="s8">➔ </span>AR, chromosome 13; inability to secrete</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Deficiency seen in Menkes disease <span class="s8">➔ </span>XR; inability to absorb Cu in duodenum;</p></li></ul><ul id="l109"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Used in hemoglobin</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;text-align: left;">Excess seen in hereditary hemochromatosis <span class="s8">➔ </span>AR, chromosome 6; leads to increased duodenal absorption of iron (i.e., cannot shut off absorption); causes Bronze diabetes <span class="s8">➔ </span>hyperpigmentation due to hemosiderin, diabetes due to Fe deposition in tail of pancreas, and various other findings such as arthritis (pseudogout), infertility, and cardiomyopathy; Tx is serial phlebotomy; chelators are the <b>wrong </b>answer in hereditary hemochromatosis; deferoxamine or deferasirox are chelators given in transfusional siderosis</p></li></ul><ul id="l110"><li><p class="s5" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;line-height: 106%;text-align: left;">Used in zinc finger domains, which are part of some transcription factors (i.e., zinc plays a role in DNA binding); zinc found in high concentrations in semen</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Deficiency causes anosmia, hypogeusia, alopecia, and diarrhea</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 34pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Acrodermatitis enteropathica <span class="s8">➔ </span>AR; inability of jejunum to absorb zinc; presents with dermatitis</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 199%;text-align: left;">42M + alcoholic + high MCV; Q asks, which combination of serum methylmalonic acid and homocysteine is most likely in this patient? <span class="s2">➔ </span>answer = normal methylmalonic acid (or methylmalonyl-CoA), t homocysteine; diagnosis is folate (B9) deficiency. Learning point is:</p><ul id="l111"><li><p style="padding-top: 1pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">B9 deficiency: normal methylmalonic acid (or methylmalonyl-CoA), t homocysteine.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">B12 deficiency: t methylmalonic acid (or methylmalonyl-CoA), t homocysteine.</p></li><li><p style="padding-top: 10pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">This is because without B9 and B12, there is less homocysteine <span class="s2">➔ </span>methionine.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">However B12 alone is needed to convert methylmalonyl-CoA into succinyl-CoA.</p></li></ul></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">Experiment performed showing HPV16 E6 protein causes p53 protein degradation; Q asks, which cellular enzyme will target p53 as a result of this viral protein? <span class="s2">➔ </span>answer = ubiquitin ligase; ubiquitination will target proteins for degradation by the proteasome.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">31F + Pap smear shows atypical squamous cells + molecular diagnostic studies show viral E6 protein; Q asks, this protein promotes cell growth and malignancy via what mechanism? <span class="s2">➔ </span>answer = “degradation of p53”; HPV16 E6 protein targets p53; HPV18 E7 protein targets RB; both are tumor</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">suppressor proteins; you can remember this because 16 comes before 18, as 6 comes before 7, as P comes before R.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">62M + back pain + restrictive cardiomyopathy + renal failure + biopsy of kidney shows a birefringent pattern with Congo red stain; Q asks, what is the structure of the material that is stained? <span class="s2">➔ </span>answer =</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 10pt;text-align: left;">�-pleated sheet; diagnosis is multiple myeloma causing cardiac and renal amyloidosis; amyloid stains</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;text-align: left;">apple green birefringent with Congo red stain because of its �-pleated sheet structure.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">Neonate + several fractures occurred during birth + shortened extremities + misshapen long bones + poor skull mineralization; Q asks, this girl has a defect in which of the following? <span class="s2">➔ </span>answer = collagen; diagnosis is osteogenesis imperfecta (collagen I).</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">Experiment with fish embryos; two pronuclei used to make embryo; results of study show that if both pronuclei are of maternal or paternal origin, the embryo fails to develop properly; why? <span class="s2">➔ </span>answer = imprinting; normally two alleles are inherited for each gene an organism has (one from each parent),</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">but various alleles will sometimes be silenced from one parent and expressed in the other; if the allele coming from mom is silenced, that’s called maternal imprinting; if the allele coming from dad is silenced, that’s called paternal imprinting.</p><ul id="l112"><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 189%;text-align: justify;">Prader-Willi syndrome (PWS; many involved genes; mental retardation + hyperphagia) is classic maternal imprinting <span class="s2">➔ </span>gene coming from mom is normally silenced; dad’s gene is supposed to be expressed but is deleted or mutated (<span class="s37">“Willi hates his dad” </span>because dad’s</p><p style="padding-top: 3pt;padding-left: 130pt;text-indent: 0pt;line-height: 213%;text-align: justify;">gene is deleted); even if mom’s gene is healthy, since it is normally silenced, it will not be expressed.</p></li><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 185%;text-align: justify;">Angelman syndrome (AS; <i>UBE3A </i>gene on chromosome 15; “happy puppet”) is classic paternal imprinting <span class="s2">➔ </span>gene coming from dad is normally silenced; mom’s gene is supposed</p><p style="padding-top: 4pt;padding-left: 130pt;text-indent: 0pt;line-height: 213%;text-align: left;">to be expressed but is deleted or mutated (<span class="s37">“Mom is not an angel” </span>because mom’s gene is deleted); even if dad’s gene is healthy, since it is normally silenced, it will not be expressed.</p></li><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 198%;text-align: left;">PWS and AS can also be caused by uniparental disomy, where both alleles are erroneously inherited from the same imprinted parent.</p><ul id="l113"><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 202%;text-align: left;">For PWS (maternal uniparental disomy), since the gene is normally maternally imprinted, if both alleles are inherited from mom, both will be silenced; disease occurs because there’s no paternal allele available to be expressed.</p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 13pt;text-align: left;">For AS (paternal uniparental disomy), since the gene is normally paternally</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 166pt;text-indent: 0pt;line-height: 213%;text-align: left;">imprinted, if both alleles are inherited from dad, both will be silenced; disease occurs because there’s no maternal allele available to be expressed.</p></li></ul></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">23M + develops pancreatic cancer + mom had colon cancer + uncle had liver cancer; investigative studies show mutation in <i>TP53 </i>gene; Q asks, which process accounts for difference in presentation among family members; answer = pleiotropy; diagnosis is Li-Fraumeni syndrome (<i>TP53 </i>gene mutation results in p53 protein abnormality).</p><ul id="l114"><li><h2 style="padding-left: 130pt;text-indent: -18pt;line-height: 206%;text-align: left;">Pleiotropy <span class="p">refers to unrelated phenotypes resulting from a mutation in a single gene. A HY USMLE example is unrelated types of cancers in family members with Li-Fraumeni syndrome. Phenylketonuria (PKU) is another HY example (i.e., mutation can result in partial albinism and mental retardation, which are unrelated phenotypic traits). Pleiotropy need not refer to</span></h2><p style="padding-top: 1pt;padding-left: 130pt;text-indent: 0pt;text-align: left;">different traits phenotypically expressed in the same individual.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 206%;text-align: left;"><b>Variable expressivity</b>, in contrast, does not specifically refer to the aspect of multiple, disparate phenotypes caused by a single gene, but instead refers to differences in <i>disease severity </i>among individuals with a condition that demonstrates a predictable spectrum of findings. For instance, NF1 is a HY example of a condition with both variable expressivity <i>and</i></p><p style="padding-top: 1pt;padding-left: 130pt;text-indent: 0pt;line-height: 212%;text-align: left;">pleiotropy. One family member might have more severe disease with café au lait spots, pheochromocytoma, neurofibromas, and Lisch nodules (iris hamartomas), whereas another family member has milder disease with only axillary/groin freckling; the difference in <i>disease severity </i>between family members along the predictable spectrum of possible features of NF1 refers to variable expressivity. The pleiotropic aspect refers to mutations in NF1 merely causing different phenotypes, such as pheochromocytoma versus café au lait spots.</p><p style="padding-top: 4pt;padding-left: 130pt;text-indent: 0pt;line-height: 213%;text-align: left;">Conditions that demonstrate variable expressivity must demonstrate complete (100%) penetrance as part of the definition.</p></li><li><h2 style="padding-left: 130pt;text-indent: -18pt;line-height: 204%;text-align: left;">Penetrance <span class="p">refers to the percentage of those with a diseased genotype who demonstrate the diseased phenotype to any degree. In other words, if 100% of those with a diseased genotype express the disease phenotypically in some form, then the disease is said to be</span></h2><p style="padding-top: 1pt;padding-left: 130pt;text-indent: 0pt;line-height: 212%;text-align: left;">completely penetrant (NF1 is an example). If the diseased genotype does not result in a disease phenotype in all individuals, then the disease is said to be incompletely penetrant (BRCA1/2 causing breast cancer that “skips a generation” is an example).</p></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: justify;">40M + pancreatic cancer due to Li-Fraumeni syndrome; Q asks, what mechanism is responsible for development of cancer in this patient? <span class="s2">➔ </span>answer = “loss of heterozygosity”; patient was born with one diseased allele in every cell (i.e., one hit); after spontaneous mutation in second allele, disease</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: justify;">occurred. The p53 protein is a tumor suppressor that halts the cell cycle in the setting of DNA damage; sometimes the Q will simply have “failure of DNA repair” as the answer for Li-Fraumeni.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: justify;">44M + cognitive decline over the past six months + abnormal movement of limbs + father had similar presentation in his 50s; Q asks, what mechanism best explains this patient’s presentation? <span class="s2">➔ </span>answer</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">= anticipation; Dx is Huntington disease (AD, chromosome 4), which is caused by 40+ trinucleotide</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">repeats (TNR) of CAG codon; anticipation is a HY term associated with TNR disorders that refers to the disease presenting increasingly more severe, and earlier, with each successive generation. This is due to expansion of the number of TNR with each generation.</p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:451pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="4"><p class="s3" style="padding-left: 121pt;padding-right: 120pt;text-indent: 0pt;line-height: 14pt;text-align: center;">Trinucleotide repeat (TNR) disorders</p></td></tr><tr style="height:13pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 7pt;padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Condition</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">TNR</p></td><td style="width:100pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Genetics</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 86pt;padding-right: 86pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY points</p></td></tr><tr style="height:98pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 7pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">Huntington</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">CAG</p></td><td style="width:100pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Chromosome 4; AD</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">and more severe onset of disease</p></td></tr><tr style="height:49pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 7pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">Friedreich ataxia</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">GAA</p></td><td style="width:100pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">Chromosome 9; AR</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 15pt;text-indent: 0pt;line-height: 12pt;text-align: left;">cavus (high-arched feet), hammer toes, early-onset type II diabetes</p></td></tr><tr style="height:49pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 7pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">Fragile X</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">CGG</p></td><td style="width:100pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 8pt;padding-right: 7pt;text-indent: 0pt;text-align: center;">X-linked dominant</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l115"><li><p class="s5" style="padding-left: 41pt;padding-right: 5pt;text-indent: -18pt;line-height: 106%;text-align: left;">Encodes huntingtin protein (yes, different spelling)</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 29pt;text-indent: -18pt;text-align: left;">Neurodegeneration with cognitive decline and choreoathetosis usually beginning in 40s or 50s</p></li><li><p class="s4" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;line-height: 106%;text-align: left;">Anticipation <span class="s5">is expansion of TNR length with each generation, resulting in earlier</span></p></li></ul><ul id="l116"><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Encodes frataxin protein</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Kyphoscoliosis, cardiomyopathy, pes</p></li></ul><ul id="l117"><li><p class="s5" style="padding-left: 41pt;padding-right: 10pt;text-indent: -18pt;line-height: 106%;text-align: justify;">Low IQ (most common hereditary cause after Down syndrome); macroorchidism, long, narrow jaw/face with everted ears</p></li><li><p class="s7" style="padding-left: 41pt;text-indent: -18pt;line-height: 11pt;text-align: left;">FMR1 <span class="s5">gene</span></p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:50pt"><td style="width:82pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 20pt;padding-right: 19pt;text-indent: 1pt;line-height: 106%;text-align: left;">Myotonic dystrophy</p></td><td style="width:52pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 15pt;padding-right: 15pt;text-indent: 0pt;text-align: center;">CTG</p></td><td style="width:100pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">Chromosome 19; AD</p></td><td style="width:217pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"/></tr></table><ul id="l118"><li><p class="s5" style="padding-left: 41pt;padding-right: 25pt;text-indent: -18pt;line-height: 106%;text-align: left;">Encodes myotonic dystrophy protein kinase</p></li><li><p class="s5" style="padding-left: 41pt;padding-right: 13pt;text-indent: -18pt;line-height: 12pt;text-align: left;">--1 ability to relax muscles (i.e., letting go of doorknob, golf club, handshake)</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: justify;">34F + tonic-clonic seizure + tingling of hands and feet + involuntary contraction of muscles of hands + hyperreflexia; Q asks which electrolyte is most likely abnormal? <span class="s2">➔ </span>answer = calcium (hypocalcemia); leads to hyperreflexia and tetany. Normal serum biochemistry:</p><ul id="l119"><li><p style="padding-top: 1pt;padding-left: 130pt;text-indent: -18pt;text-align: justify;">Calcium: 8.4-10.2 mg/dL</p><ul id="l120"><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;line-height: 25pt;text-align: left;">Low Ca causes “up” presentation of tetany and hyperreflexia; high Ca causes “down” presentation of muscle flaccidity and hyporeflexia; high Ca also associated with delirium/confusion (hypercalcemic crisis).</p></li><li><p style="padding-top: 9pt;padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">High calcium HY causes are sarcoidosis (due to t vitamin D), primary hyperparathyroidism (adenoma, hyperplasia, MEN 1/2A), metastatic malignancy,</p><p style="padding-top: 2pt;padding-left: 166pt;text-indent: 0pt;text-align: left;">multiple myeloma, and thiazides (cause t Ca reabsorption in DCT).</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 200%;text-align: left;">Low calcium HY causes are rickets/osteomalacia (--1 vitamin D), secondary hyperparathyroidism (renal failure), post-thyroidectomy (concomitant loss of parathyroids), DiGeorge syndrome (agenesis of 3<span class="s15">rd</span><span class="s16"> </span>and 4<span class="s15">th</span><span class="s16"> </span>pharyngeal pouches), and</p><p style="padding-top: 1pt;padding-left: 166pt;text-indent: 0pt;line-height: 213%;text-align: left;">loop diuretics (--1 paracellular reabsorption), hypomagnesemia (hypo-Mg can cause hypo-Ca and hypo-K non-responsive to supplementation; usually seen in alcoholics).</p></li></ul></li><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Sodium: 135-145 mEq/L</p><ul id="l121"><li><p style="padding-top: 10pt;padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">Sodium derangement (high and low) causes CNS dysfunction <span class="s2">➔ </span>confusion, stupor, or coma.</p></li><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;line-height: 195%;text-align: left;">Na can often be <b>normal </b>in USMLE vignettes despite your expectation that it might be characteristically deranged – e.g., patient has Conn syndrome and yet the sodium is normal, and you’re like wtf? (because you expect it to be elevated) <span class="s2">➔ </span>this is <b>typical </b>for USMLE vignettes.</p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">High Na HY causes are primary hyperaldosteronism, renal artery stenosis, fibromuscular dysplasia, dehydration, diabetes insipidus.</p></li><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;text-align: left;">Low Na HY causes are Addison disease, psychogenic polydipsia, SIADH.</p></li></ul></li><li><p style="padding-top: 4pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">Potassium: 3.5-5.0 mEq/L</p><ul id="l122"><li><p style="padding-top: 10pt;padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">Potassium derangement (high and low) causes cardiac dysfunction <span class="s2">➔ </span>arrhythmia (contrast this with Na, which causes CNS dysfunction).</p></li><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">High K HY causes are Addison disease, renal failure, polypharmacy with agents such as potassium-sparing diuretics and digoxin.</p></li><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">Low K HY causes are primary hyperaldosteronism, renal artery stenosis, fibromuscular dysplasia, Cushing disease (chronically high glucocorticoid levels can</p><p style="padding-top: 2pt;padding-left: 166pt;text-indent: 0pt;line-height: 213%;text-align: left;">cause hypo-K due to distal renal secretion similar to mineralocorticoids), vomiting, diarrhea, loop diuretics and thiazides, and hypomagnesemia (hypo-Mg can cause hypo-K and hypo-Ca non-responsive to supplementation; usually seen in alcoholics).</p></li></ul></li><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Phosphate: 2.5-4.5 mg/dL</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l123"><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 204%;text-align: left;">High phosphorus HY causes are hypoparathyroidism, secondary hyperparathyroidism, renal failure, tumor lysis syndrome, and sarcoidosis (t vitamin D).</p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">Low phosphorus HY causes are primary hyperparathyroidism, rickets / osteomalacia, and refeeding syndrome.</p></li></ul></li><li><p style="padding-top: 2pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">Magnesium: 1.7-2.2 mg/dL</p><ul id="l124"><li><p style="padding-top: 10pt;padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">Magnesium derangement causes effects similar to Ca – i.e., low Mg presents with an “up” state of hyperreflexia and increased muscle tone; high Mg presents with a</p><p style="padding-top: 2pt;padding-left: 166pt;text-indent: 0pt;text-align: left;">“down” state of hyporeflexia and muscle flaccidity.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">Low Mg HY cause is alcoholism (decreased dietary intake) <span class="s2">➔ </span>leads to hypocalcemia and hypokalemia non-response to supplementation.</p><p style="padding-top: 2pt;padding-left: 112pt;text-indent: 0pt;text-align: left;"><span class="s14">o </span>pH: 7.35-7.45; HCO<span class="s20">3</span><span class="s15">-</span>: 22-28 mEq/L; pCO<span class="s20">2</span>: 33-44 mmHg</p></li><li><p style="padding-top: 10pt;padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">Metabolic acidosis <span class="s2">➔ </span>low pH caused by low HCO3; pCO2 will go down to compensate (CO2 is acidic).</p></li><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">MUDPILES is mnemonic for high-anion-gap metabolic acidoses <span class="s2">➔ </span>Methanol, Uremia (renal failure), DKA, Phenformin (weird drug you don’t need to worry about), Iron</p><p style="padding-top: 2pt;padding-left: 166pt;text-indent: 0pt;text-align: left;">tablets + Isoniazid, Lactic acidosis, Ethylene glycol (antifreeze), Salicylates (aspirin).</p><p style="padding-top: 4pt;padding-left: 166pt;text-indent: 0pt;line-height: 213%;text-align: left;">If the patient has metabolic acidosis and the anion gap is normal in the Q, you can eliminate the MUDPILES answers and choose an answer like renal tubular acidosis.</p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Renal tubular acidosis, Addison, and diarrhea are HY for normal anion gap.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 192%;text-align: left;">Anion gap is calculated as Na - (HCO3 + Cl); normal is 8-12 mEq/L; high is 13 or greater.</p></li><li><p style="padding-top: 1pt;padding-left: 166pt;text-indent: -18pt;line-height: 191%;text-align: left;">Metabolic alkalosis <span class="s2">➔ </span>high pH caused by high HCO3; pCO2 will go up to compensate.</p><ul id="l125"><li><p style="padding-top: 2pt;padding-left: 202pt;text-indent: -18pt;line-height: 213%;text-align: left;">Conn syndrome, renal artery stenosis, fibromuscular dysplasia, vomiting, loops and thiazides (promote RAS activation due to volume depletion).</p></li></ul></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Respiratory acidosis <span class="s2">➔ </span>low pH caused by high CO2; HCO3 goes up <i>if chronic </i>to</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 166pt;text-indent: 0pt;text-align: left;">compensate (bicarb is basic).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l126"><li><p style="padding-left: 202pt;text-indent: -18pt;line-height: 213%;text-align: left;">Acute (<b>normal </b>bicarb): hypoventilation due to opioids, benzos, barbiturates.</p></li><li><p style="padding-left: 202pt;text-indent: -18pt;line-height: 213%;text-align: left;">Chronic (high bicarb): COPD, obstructive sleep apnea, obesity, ankylosing spondylitis, severe kyphoscoliosis.</p></li></ul></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Respiratory alkalosis <span class="s2">➔ </span>high pH caused by low CO2; HCO3 goes down <i>if chronic </i>to</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 166pt;text-indent: 0pt;text-align: left;">compensate.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l127"><li><p style="padding-left: 202pt;text-indent: -18pt;line-height: 213%;text-align: left;">Acute (<b>normal </b>bicarb): asthma attack, panic attack, most pulmonary emboli, altitude sickness (first day at high altitude).</p></li><li><p style="padding-left: 202pt;text-indent: -18pt;line-height: 213%;text-align: left;">Chronic (<b>low </b>bicarb): living at high altitude, pregnancy (progesterone upregulates respiratory center).</p></li></ul></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Should be noted that primary metabolic acid/base derangements are compensated</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 166pt;text-indent: 0pt;line-height: 212%;text-align: left;">for instantly by changes in respiration (i.e., it’s easy to retain or breathe off CO2 merely by changing respiratory rate), whereas primary respiratory derangements are compensated for <b>slowly </b>because it takes time for the kidney to alter bicarb excretion.</p></li><li><p style="padding-left: 166pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Winter formula is used to calculate predicted pCO2 based on any change in bicarb,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 166pt;text-indent: 0pt;text-align: left;">where: Predicted pCO2 = (1.5xHCO3) + 8 +/- 2. For example, if a patient has DKA</p><p style="padding-top: 4pt;padding-left: 166pt;text-indent: 0pt;line-height: 212%;text-align: justify;">and bicarb is 14 mEq/L, we expect pCO2 to be 27-31 mmHg. If pCO2 is lower than 27, then the patient has a concurrent respiratory alkalosis; if higher than 31, then the patient has a concurrent respiratory acidosis.</p></li></ul></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">71M + has an MI + revascularization is achieved via percutaneous coronary intervention + serum troponin + CK-MB increase following the procedure; Q asks why? <span class="s2">➔ </span>answer = “membrane lipid peroxidation”; reperfusion injury occurs due to oxygen radicals following coronary revascularization.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 206%;text-align: left;">15M + intermittent orthostatic hypotension + low serum norepinephrine concentration + high serum dopamine concentration; which enzyme is deficient? <span class="s2">➔ </span>answer = dopamine �-hydroxylase.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 61pt;text-indent: 0pt;text-align: left;"><span><img width="601" height="121" alt="image" src="Image_028.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">6-month-old boy + musty/mousy body odor + fairer skinned compared to siblings + slow mental progression; Q asks, this condition could have been prevented how? <span class="s2">➔ </span>answer = “routine newborn screening”; Dx is phenylketonuria (PKU); picked up on heel-prick test at birth; deficiency of phenylalanine hydroxylase (cannot convert phenylalanine <span class="s2">➔ </span>tyrosine); results in mental retardation; newborn screening test must be tt sensitive to best pick it up; Tx = avoid phenylalanine in diet.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">1M + increased serum phenylalanine; Q asks what is deficient in this patient (answers are all substrates and cofactors rather than enzymes); answer = tetrahydrobiopterin (BH4, THB), which is a cofactor for phenylalanine hydroxylase; Dx is malignant PKU, which is PKU due to BH4 deficiency rather than phenylalanine hydroxylase deficiency.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">18M + goes for long run + depletes glucose stores; Q asks, which organ, in addition to the liver, will release newly produced glucose in the patient? <span class="s2">➔ </span>answer = kidney; the kidney and liver are both able to carry out gluconeogenesis. Skeletal muscle notably cannot produce glucose because it lacks</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">glucose-6-phosphatase.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">20M + 6-year-Hx of seizure disorder + flesh-colored papules on bridge of nose and in the nasolabial folds; diagnosis? <span class="s2">➔ </span>answer = tuberous sclerosis (TSC); AD; chromosomes 9 and 16 (hamartin and tuberin proteins); subependymal or periventricular nodules seen on MRI; hypopigmented macules</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">(ash leaf spots); hyperpigmented velvety lesions (shagreen patches); cardiac rhabdomyoma; renal angiomyolipoma; subungual fibromas (nailbed tumors); vignette will also give a young child who has writhing movements in his/her sleep to suggest seizures.</p><table style="border-collapse:collapse;margin-left:36.65pt" cellspacing="0"><tr style="height:15pt"><td style="width:503pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="3"><p class="s3" style="padding-left: 133pt;padding-right: 133pt;text-indent: 0pt;line-height: 14pt;text-align: center;">Phakomatoses (neurocutaneous disorders)</p></td></tr><tr style="height:13pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 7pt;padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Condition</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Genetics</p></td><td style="width:212pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s4" style="padding-left: 84pt;padding-right: 83pt;text-indent: 0pt;line-height: 11pt;text-align: center;">HY points</p></td></tr><tr style="height:74pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 7pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">Neurofibromatosis type I (NF1)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s7" style="padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">NF1<span class="s5">; AD; chromosome 17</span></p></td><td style="width:212pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 8pt;text-indent: -18pt;line-height: 106%;text-align: left;">-   Neurofibromas, café au lait spots (hyperpigmented macules), axillary/groin freckling, Lisch nodules (iris hamartomas), pheochromocytoma, optic nerve glioma, oligodendroglioma,</p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">ependymoma</p></td></tr><tr style="height:25pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 7pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">Neurofibromatosis type II (NF2)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s7" style="padding-top: 6pt;padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">NF2<span class="s5">; AD; chromosome 22</span></p></td><td style="width:212pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;">-  Bilateral acoustic schwannomas,</p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">meningioma</p></td></tr><tr style="height:86pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 9pt;padding-left: 7pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">Tuberous sclerosis (TSC)</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s7" style="padding-left: 55pt;padding-right: 20pt;text-indent: -34pt;text-align: left;">TSC1<span class="s5">; AD; chromosome 9; hamartin</span></p><p class="s7" style="padding-left: 59pt;padding-right: 17pt;text-indent: -41pt;line-height: 106%;text-align: left;">TSC2 <span class="s5">; AD; chromosome 16; tuberin</span></p></td><td style="width:212pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 5pt;text-indent: -18pt;line-height: 106%;text-align: left;">-  Periventricular nodules (tubers) on MRI of head, seizures, adenoma sebaceum (angiofibromas), subungual fibromas, renal angiomyolipoma, cardiac rhabdomyoma, hypopigmented macules</p><p class="s5" style="padding-left: 41pt;padding-right: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;">(“ashleaf spots”), hyperpigmented velvety lesions (“shagreen patches”)</p></td></tr><tr style="height:62pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 10pt;padding-left: 7pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">Von Hippel-Lindau</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s7" style="padding-top: 10pt;padding-left: 8pt;padding-right: 8pt;text-indent: 0pt;text-align: center;">VHL<span class="s5">; AD; chromosome 3</span></p></td><td style="width:212pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">of hypoxia-inducible factor</p></td></tr><tr style="height:61pt"><td style="width:142pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-top: 10pt;padding-left: 7pt;padding-right: 6pt;text-indent: 0pt;text-align: center;">Sturge-Weber</p></td><td style="width:149pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s5" style="padding-left: 45pt;text-indent: -39pt;line-height: 106%;text-align: left;">Not inherited; somatic mosaicism of <i>GNAQ </i>gene</p></td><td style="width:212pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 41pt;padding-right: 14pt;text-indent: -18pt;line-height: 106%;text-align: left;">-   Port wine stain birth mark (nevus flammeus; may also present as violaceous papules in temporal distribution), leptomeningeal angioma</p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(presenting as seizure); glaucoma</p></td></tr></table><ul id="l128"><li><p class="s5" style="padding-left: 41pt;padding-right: 5pt;text-indent: -18pt;line-height: 106%;text-align: left;">Cerebellar/retinal hemangioblastomas, bilateral renal cell carcinoma, pancreatic cysts</p></li><li><p class="s5" style="padding-left: 41pt;text-indent: -18pt;text-align: left;">Mutation causes constitutive activation</p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 206%;text-align: left;">Experiment is performed showing a nutrient causes increased gene products detectable by Western blotting + no change in gene products detected by Northern blotting or PCR; Q asks, what does the nutrient cause intracellularly? <span class="s2">➔ </span>answer = “translation of mRNA”; Western blot detects protein;</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Northern blot detects RNA; Southern blot detects DNA; PCR detects DNA. Transcription is the process</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;text-align: left;">of DNA <span class="s2">➔ </span>RNA; translation is the process of RNA <span class="s2">➔ </span>protein.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:58.25pt" cellspacing="0"><tr style="height:15pt"><td style="width:450pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt" colspan="2"><p class="s3" style="padding-left: 150pt;padding-right: 150pt;text-indent: 0pt;line-height: 13pt;text-align: center;">Annoying lab techniques</p></td></tr><tr style="height:13pt"><td style="width:163pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 42pt;padding-right: 41pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Northern blot</p></td><td style="width:287pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-  Detects RNA</p></td></tr><tr style="height:13pt"><td style="width:163pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 42pt;padding-right: 41pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Southern blot</p></td><td style="width:287pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-  Detects DNA</p></td></tr><tr style="height:13pt"><td style="width:163pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 42pt;padding-right: 41pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Western blot</p></td><td style="width:287pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-  Detects protein</p></td></tr><tr style="height:13pt"><td style="width:163pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 42pt;padding-right: 41pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Southwestern blot</p></td><td style="width:287pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-  Detects DNA-binding proteins</p></td></tr><tr style="height:25pt"><td style="width:163pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-top: 6pt;padding-left: 42pt;padding-right: 41pt;text-indent: 0pt;text-align: center;">ELISA</p></td><td style="width:287pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;text-align: left;">-  Detects presence of antigen (direct ELISA) or antibody</p><p class="s5" style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(indirect ELISA) in patient sample</p></td></tr><tr style="height:13pt"><td style="width:163pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 42pt;padding-right: 41pt;text-indent: 0pt;line-height: 11pt;text-align: center;">PCR</p></td><td style="width:287pt;border-top-style:solid;border-top-width:1pt;border-left-style:solid;border-left-width:1pt;border-bottom-style:solid;border-bottom-width:1pt;border-right-style:solid;border-right-width:1pt"><p class="s5" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">-  Amplifies DNA fragments in order to make many copies</p></td></tr></table></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">Experiment is performed visualizing changes to RNA via electron microscopy; Q asks which change occurs in the cytosol? <span class="s2">➔ </span>answer = “association with P-bodies”; DNA is transcribed to hnRNA (heteronuclear RNA); hnRNA then undergoes three main changes in the nucleus: 1) addition of poly-A</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">tail to 3’ end, 2) addition of 7-methylguanosine cap to 5’ end, and 3) splicing out of introns; after these three changes are made in the nucleus, the hnRNA is now called mRNA (messenger RNA). The mRNA then leaves the nucleus for the cytoplasm, where it associates with P-bodies, which are “docking centers” for mRNA to be sequestered and translated at a later point in time.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 12pt;text-align: left;">28F + experiences spontaneous abortion; Q asks, what’s the most likely mechanism for this? <span class="s2">➔</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">answer = “unbalanced chromosomal rearrangement,” which is the most common cause of spontaneous abortion.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 215%;text-align: left;">Investigator looking at cellular effects of increased serum insulin; which of the following combinations of findings is most likely; answer = t nuclear/cytoplasmic shuttling; t serine phosphorylation; --1 ubiquitination; insulin activates MAP tyrosine kinase and serine/threonine pathways, which will cause t nuclear/cytoplasmic shuttling and t serine phosphorylation; ubiquitination is --1 because this is a catabolic process but insulin is anabolic.</p></li><li><p style="padding-bottom: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 211%;text-align: left;">20M + weakness + twitching + muscle biopsy shows ragged red fibers; Q asks which cellular organelle on the following diagram is fucked up.</p><p style="padding-left: 61pt;text-indent: 0pt;text-align: left;"><span><img width="594" height="334" alt="image" src="Image_029.jpg"/></span></p><ul id="l129"><li><p style="padding-top: 4pt;padding-bottom: 2pt;padding-left: 130pt;text-indent: -18pt;line-height: 198%;text-align: left;">Answer = mitochondrion; “ragged red fibers” is buzzy description seen in myoclonic epilepsy with ragged red fibers (MERRF syndrome).</p><p style="padding-left: 67pt;text-indent: 0pt;text-align: left;"><span><img width="584" height="333" alt="image" src="Image_030.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 208%;text-align: left;">4M + Hx of recurrent ear infections + hepatosplenomegaly + studies show deficient <i>N</i>- acetylglucosamine-1-phosphotransferase + analysis of skin fibroblasts shows they secrete large amounts of acid hydrolase into the culture medium; Q asks, these hydrolase enzymes are unable to target to which organelle? <span class="s2">➔ </span>answer = lysosome; diagnosis is I-cell disease; deficient enzyme leads to</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 10pt;text-align: left;">inability to produce mannose-6-phosphate, which normally enables hydrolases at the Golgi to be</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">targeted to the lysosomes; if the Q asks for the location of the deficient enzyme, choose Golgi; if the Q asks for the location the hydrolases cannot be targeted to, choose lysosomes. Presentation is normally restricted joint movement + coarse facial features, but can also present as recurrent ear infections and hepatosplenomegaly.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: justify;">3M + developmental delay + ophthalmoplegia + hypotonia + hearing loss in mother + uncle had stroke-like episodes in his 20s; Q asks, which mechanism explains the findings in this family? <span class="s2">➔ </span>answer = heteroplasmy; diagnosis is a mitochondrial disorder (in this case, MELAS, which is</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes); you don’t need to know MELAS specifically, but just know ear and/or eye problems, lactic acidosis, and hypotonia suggest mitochondrial disorders in general; mitochondrial disorders are always maternally inherited (i.e., only females pass on to offspring); heteroplasmy is variation of mitochondrial disease severity based on</p><p style="padding-top: 4pt;padding-bottom: 2pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">the proportion of diseased mitochondrial DNA (not chromosomal DNA) inherited; each oocyte from the mom will have hundreds to thousands of copies of mitochondrial DNA with differing proportions of diseased vs healthy copies, leading to offspring with varying disease severity. Heteroplasmy is specifically applied to this process for mitochondrial diseases; in contrast, variable expressivity is applied to disorders with complete penetrance that are <i>not </i>mitochondrial (e.g., NF1).</p><p style="padding-left: 128pt;text-indent: 0pt;text-align: left;"><span><img width="408" height="324" alt="image" src="Image_031.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">Neonate + marked hypopigmentation + blue irides; Q asks, this condition is caused by a defective enzyme located in which organelle? <span class="s2">➔ </span>answer = melanosome; diagnosis is albinism, which is usually caused by deficient/defective tyrosinase, a melanosomal enzyme.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">27M + severe muscle cramping with exercise + venous blood sampling shows post-exercise lactic acid does not increase compared to pre-exercise levels; Q asks, which enzyme is most likely deficient? <span class="s2">➔ </span>answer = muscle glycogen phosphorylase; diagnosis is McArdle syndrome (glycogen storage disease</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">type V).</p></li><li><p style="padding-top: 2pt;padding-left: 94pt;text-indent: -18pt;line-height: 25pt;text-align: left;">16F + gives birth to neonate with epicanthal folds, slanted palpebral fissures, single palmar crease, and low IQ; karyotyping of the neonate shows abnormality in 100% of cells; what’s the most likely mechanism for her child’s condition? <span class="s2">➔ </span>answer = Robertsonian translocation; child has Down syndrome (trisomy 21) due to inheriting the long arm of chromosome 21 attached to chromosome 14</p><p style="padding-top: 9pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">of one of the parents – i.e., t(14q;21q). The implication is that it is unlikely to have meiotic nondisjunction in the female at such a young age (1/100 chance at age 40; 1/10 chance at age 50); if</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 206%;text-align: left;">child is mosaic Down, then mechanism is “post-fertilization mitotic error” (i.e., error occurred during cell division after fertilization). Robertsonian accounts for 4% of Down, mosaicism 1%, nondisjunction 95%. Down syndrome <span class="s2">➔ </span>epicanthal folds, slanted palpebral fissures, flattened facies, single palmar</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 10pt;text-align: left;">crease, and low IQ, endocardial cushion defects (AVSD), pulmonary arterial malformations,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">hypothyroidism, Eustachian tube atresia (recurrent otitis media + hearing loss), Brushfield spots (white spots found on periphery of iris); tri-screen in first trimester of pregnancy at 8-10 weeks shows</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 218%;text-align: left;">--1 PAPP-A, t �-hCG, t nuchal translucency; ultrasound shows hypoplastic nasal bone (flattened facies); quad screen in second trimester of pregnancy at 16-20 weeks shows --1 AFP, t �-hCG, --1 estriol, t inhibin-A (two ways to remember: 1) put the variables in alphabetical order, then just know it’s down, up, down, up; OR, 2) the variables that have an “H” in them are the ones that have t arrows).</p></li><li><p style="padding-left: 94pt;text-indent: -94pt;line-height: 11pt;text-align: left;">Neonate born with microcephaly + prominent occiput + clenched hands + low-set ears; what</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 191%;text-align: left;">chromosomal abnormality is most likely to be seen? <span class="s2">➔ </span>answer = trisomy of chromosome 18; diagnosis is Edward syndrome; presentation is microcephaly + prominent occiput + clenched hands +</p><p style="padding-top: 2pt;padding-left: 94pt;text-indent: 0pt;line-height: 217%;text-align: left;">low-set ears; flattened facies <b>not </b>characteristic (that’s Down due to hypoplastic nasal bone); second trimester quad screen shows --1 for all four variables: AFP, �-hCG, estriol, inhibin-A.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 213%;text-align: left;">Neonate born with holoprosencephaly + cleft lip; Q asks about chromosomal abnormality; answer = trisomy of chromosome 13; Dx is Patau syndrome.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">42F + has a tumor demonstrating G-alpha-s G-proteins that lack GTPase function; Q asks, which cellular change would be seen in this patient? <span class="s2">➔ </span>answer = increased cAMP; cleavage of GTP into GDP functions to shut off G-protein activity, so loss of GTPase function means increased activity; G-alpha-s</p><p style="padding-top: 1pt;padding-left: 79pt;text-indent: 0pt;text-align: center;">G-proteins increase cAMP, so in this case the tumor leads to increased cAMP production.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">Neonate with rare disease has a mutation localized to an intron sequence; Q asks, which of the following mechanisms most likely accounts for disease in this patient? <span class="s2">➔ </span>answer = “RNA splice error”; introns are sequences that are not translated into protein; exons are sequences that can be</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">translated into protein; a HY USMLE point regarding introns is that they play a role in post- transcriptional RNA splicing.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 213%;text-align: left;">Neonate + high serum BUN + normal creatinine; a defect in ammoniagenesis; Q asks, which substrate is the most likely source of the ammonia; answer = glutamine; ammonia is produced from the</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">breakdown of various amino acids with amino group side-chains; the ammonia is processed via the urea cycle into urea, which is much less toxic.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 60pt;text-indent: 0pt;text-align: left;"><span><img width="618" height="462" alt="image" src="Image_032.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -94pt;text-align: right;">21M + t serum orotic acid + hyperammonemia + --1 blood urea nitrogen + normal RBC MCV; Dx? <span class="s2">➔</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">answer = ornithine transcarbamylase deficiency; urea cycle disorder; X-linked recessive; orotic acid is normally produced from carbomyl phosphate (via CPS-II) in the synthesis of pyrimidines; in ornithine transcarbamylase deficiency, since the urea cycle isn’t working, carbamoyl phosphate is shunted toward orotic acid; hyperammonemia results from less conversion of NH3 to urea; MCV is normal because pyrimidine synthesis is not impaired; blood urea nitrogen is decreased because less urea is being produced.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 213%;text-align: left;">Neonate + poor feeding + lethargy + vomiting + increased serum orotic acid + hyperammonemia; which enzyme is deficient; answer = ornithine transcarbamylase.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 13pt;text-align: left;">21M + t serum orotic acid + t RBC MCV + serum B9 and B12 levels are normal; Dx? <span class="s2">➔ </span>answer =</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: right;">orotic aciduria; caused by deficiency of uridine monophosphate synthase, an enzyme required for</p><p style="padding-top: 4pt;padding-bottom: 2pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">pyrimidine synthesis; MCV is increased because pyrimidine synthesis is impaired; ammonia is normal (in contrast to ornithine transcarbamylase deficiency) because the urea cycle is intact.</p><p style="padding-left: 71pt;text-indent: 0pt;text-align: left;"><span><img width="567" height="271" alt="image" src="Image_033.jpg"/></span></p></li><li><p style="padding-top: 10pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">8-month-old girl + hyperammonemia + decreased serum citrulline + increased serum glutamine + increased serum orotic acid; which enzyme is deficient in this patient? <span class="s2">➔ </span>answer = ornithine transcarbamylase deficiency; should be noted this is X-linked recessive but Step 1 NBME gives the</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">condition in a girl; apart from the inheritance pattern discrepancy making no sense, the only way to arrive at the answer is because the combination of vignette findings points toward the deficiency; if urea cycle is impaired, glutamine cannot liberate ammonia into the urea cycle (so glutamine and ammonia build up); citrulline is decreased simply because it is one of the intermediates of the urea cycle; orotic acid is increased because the ammonia is shunted down pyrimidine synthesis instead (orotic acid is one of the intermediates); wrong answer is deficiency of carbamoyl phosphate synthetase because this enzyme is required for orotic acid synthesis. It’s a poor Q because the disease is XR and the presentation is in a girl, but it’s literally what’s on the NBME.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 206%;text-align: left;">5M + progressive weakness and loss of muscle function + exam shows hypertrophy of calf muscles + serum CK is elevated; the most likely cause of this presentation is a defective protein in which area of muscle? <span class="s2">➔ </span>answer = cytoskeleton; diagnosis is Duchenne (XR); dystrophin protein (<i>DMD </i>gene) is</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 10pt;text-align: left;">required to connect muscle cell cytoskeleton to extracellular proteins; pseudohypertrophy results</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">from fibroadipose tissue deposition; Gower maneuver classic for Duchenne; Duchenne is caused by frameshift or nonsense mutations, resulting in truncated, non-functional protein; Becker is less severe</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">and presents in teenage or young adult years and is usually caused by missense mutations or insertions/deletions of entire codons.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">Girl with asthma is administered IV methylprednisolone, resulting in marked clinical improvement; what’s the mechanism via which this agent resulted in improvement? <span class="s2">➔ </span>answer = “binding to cytoplasmic receptor, translocation to nucleus, and transcriptional activation of target genes”; most</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">steroid hormones bind to intracytoplasmic receptors, as is the case additionally for androgens, estrogens, progestins, glucocorticoids, and mineralocorticoids; thyroid hormone (T3/T4) bind to intranuclear receptors.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 215%;text-align: left;">Experiment is performed analyzed nuclear factor-kappa B (NF-KB); Q asks about role of IKB in relation to NF-KB; answer = “releases NF-KB after undergoing phosphorylation”; outrageously dumb and pedantic, but it’s on the NBME so just memorize it.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">Experiment is performed where an agent inhibits histone deacetylase; this drug most likely affects which cellular process? <span class="s2">➔ </span>answer = transcription; histones are highly compacted structures of heterochromatic DNA; process of acetylation normally activates and makes DNA euchromatic (i.e.,</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 217%;text-align: left;">transcribable); methylation normally silences and makes DNA heterochromatic (i.e., not transcribable); histone deacetylase t silencing (i.e., --1 acetylation) and t heterochromatin.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 206%;text-align: left;">42M + receives all-<i>trans </i>retinoic acid for Tx of AML M3 (APL); Q asks, which enzyme will be attracted to the retinoic acid receptor/promyelocytic leukemia fusion protein to form a pre-transcriptional complex? <span class="s2">➔ </span>answer = histone acetylase; wrong answer is histone <i>N</i>-methyltransferase; learning point</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 10pt;text-align: left;">for USMLE is that acetylation is usually associated with gene activation; methylation is usually</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 211%;text-align: left;">associated with gene silencing. Epigenetics is the study of how gene expression can be modified without changes made to nucleic acid sequences (i.e., instead through methylation, acetylation, etc.).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">80M + alcohol dependence + many ecchymoses + few teeth + hemorrhagic macules around hair follicles; what is most likely responsible for his poor wound healing? <span class="s2">➔ </span>answer = inadequate hydroxylation of collagen polypeptides; Dx is scurvy (vitamin C deficiency); vitamin C is necessary for</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">hydroxylation of proline and lysine residues in developing collagen; perifollicular hemorrhages are a HY finding for scurvy; bleeding around gums, poor wound healing, and easy bruising are common.</p></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">30M + palpitations + weight loss + exophthalmos + tremors; Q asks, patient’s presentation is most likely due to hormonal action on which of the following receptors? <span class="s2">➔ </span>answer = “nuclear/retinoid X binding to DNA”; thyroid hormones bind intranuclear.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">A couple who are both healthy have two children with achondroplasia; what’s the most likely mechanism for this process? <span class="s2">➔ </span>answer = germline mosaicism; achondroplasia is an AD disorder but most cases are due to <i>de novo </i>mutations within one of the spermatogonia or oogonia of the parents</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">(i.e., a % of germline cells are affected), but the somatic (body) cells of the parents are completely normal (i.e., this is <i>not </i>somatic mosaicism); germline mosaicism is important in explaining how it’s possible for an individual to have an AD disorder, where 100% of their somatic cells are affected, despite both parents being both phenotypically and genotypically normal. In contrast, somatic mosaicism is due to a post-fertilization mitotic error and is the mechanism via which a patient could have a % of somatic cells normal and a % diseased (e.g., a mosaic Turner or Down patient).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">24F + lost in wilderness for three weeks; Q asks how adipocytes play an important role in maintaining homeostasis; answer = “glucagon activates hormone-sensitive lipase”; HSL will liberate fatty acids from the adipocytes into the blood to be used as energy. Insulin does the opposite by activating lipoprotein lipase; this brings fatty acids from the blood into the adipocytes.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">19M + mental retardation + long face + prominent ears + large testes; analysis of patient’s DNA shows 400 CGG repeats in the <i>FMR1 </i>gene 5’ untranslated region; which of the following would most likely result from this expansion of nucleotide repeats? <span class="s2">➔ </span>answer = “decreased transcription”; Dx is Fragile X, which is due to TNR expansion &gt;200 repeats of CGG; expansion of untranslated region results in</p><p style="padding-left: 94pt;text-indent: 0pt;text-align: left;">hypermethylation of <i>FMR1 </i>gene and prevents binding of transcription factors and RNA polymerase.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 206%;text-align: left;">6-month-old boy + jaundice + cataracts + hepatomegaly; urine shows positive reaction to copper reduction test and negative reaction to a test agent that contains glucose oxidase; what enzyme is deficient in this patient? <span class="s2">➔ </span>answer = galactose-1-phosphate uridyltransferase (classic galactosemia);</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 9pt;text-align: left;">if the Q mentioned cataracts alone, answer would be galactokinase deficiency; the galactose</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">disorders appear shortly after birth because lactose in breast milk (or cow’s milk) is broken down into glucose and galactose; in contrast, fructose disorders appear later when the child is started on juice, fruit, honey, and table sugar, where sucrose is broken down into glucose and fructose.</p></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">Neonate has blue sclerae, hyperextensible joints, fragile bones, and dysplasia of his enamel; which mechanism accounts for the pleiotropic effects of osteogenesis imperfecta in this patient? <span class="s2">➔ </span>answer</p><p style="text-indent: 0pt;line-height: 10pt;text-align: right;">= “expression of defective gene in multiple tissues”; pleiotropy once again is one gene resulting in</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;text-align: left;">different unrelated phenotypes.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">2F + cherry red spot on macula + deficiency of hexosaminidase A; this patient is most likely to have a buildup of what? <span class="s2">➔ </span>answer = GM2 ganglioside; Dx is Tay-Sachs.</p></li><li><p style="padding-left: 94pt;text-indent: -94pt;line-height: 10pt;text-align: right;">Investigator looking at mitochondrial tRNA and finds mitochondria encode their own tRNA; Q asks</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 192%;text-align: left;">why? <span class="s2">➔ </span>answer = “mitochondria use a non-standard genetic code”; mitochondria have their own genes separate from chromosomal DNA.</p></li><li><p style="padding-top: 2pt;padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">17F + asks about breastfeeding and immunity for her baby; physician explains IgA moves through epithelial cells and is secreted into duct lumina; Q asks which process is best described here; answer = transcytosis, which is movement of substrates from outside one side of the cell, <i>through </i>the interior of the cell, and then out the other side of the cell; this is in contrast to exocytosis, which is merely secreting substrates from inside the cell to the outside; endocytosis is a broad term referring to the internalization of substrates from outside the cell to within; phagocytosis is the engulfment of solid particles; pinocytosis is the engulfment of liquid.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">50F + positive PPD test + negative chest x-ray + commenced on prophylactic therapy; 6 months later patient develops decreased sensation to pinprick in all extremities; Dx? <span class="s2">➔ </span>answer = vitamin B6 deficiency secondary to isoniazid.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">3F + tonic-clonic seizure; Q asks, the Tx for this condition mediates its effect via which type of molecular target; answer = “ligand-gated ion channels”; benzos, e.g., diazepam, are used first-line for status epilepticus; they agonize GABA<span class="s20">A</span>, which causes chloride to enter the neuron, hyperpolarizing it. GABA is normally the ligand that binds to its receptor, activating the chloride channel.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">2M + bites his fingers and lips + orange-red crystals in his diaper; which enzyme is deficient in this patient? <span class="s2">➔ </span>answer = hypoxanthine-guanine phosphoribosyltransferase (HGPRT); Dx is Lesch-Nyhan syndrome; X-linked recessive; congenital cause of uric acid overproduction (gout); self-mutilation</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">common; HGPRT is necessary for recycling of purines; if enzyme missing, hypoxanthine and guanine are shunted to uric acid; red-orange sand-like uric acid crystals seen in diaper.</p></li><li><p style="padding-top: 3pt;padding-left: 94pt;text-indent: -18pt;line-height: 192%;text-align: left;">2F + potbelly + hypotonia + large tongue; Dx? <span class="s2">➔ </span>answer = cretinism (congenital hypothyroidism); can leads to mental retardation (thyroid hormone needed for myelin synthesis); impaired bone growth.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 192%;text-align: left;">2F + potbelly + fed gruel; Dx? <span class="s2">➔ </span>answer = “protein-calorie malnutrition” (kwashiorkor) – i.e., sufficient calories but insufficient protein.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;text-align: left;">2F + severely underweight with wasting; Dx? <span class="s2">➔ </span>answer = “total calorie malnutrition” (marasmus).</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: justify;">3M + severe combined immunodeficiency + receives gene therapy delivered via lysogenic phage + treatment successful; six months later he develops leukemia; why? <span class="s2">➔ </span>answer = virus incorporated itself next to oncogene; since the treatment was successful, we know the delivered gene was</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: justify;">successfully incorporated and transcribed, so for there to be leukemia means an oncogene may have been nearby and erroneously also transcribed.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">10M + recurrent nosebleeds + bleeding time 6 minutes + platelet count 200,000 + Hb 13.5 g/dL + facial telangiectasias; Q asks, what’s the inheritance pattern of this condition? <span class="s2">➔ </span>answer = autosomal dominant; Dx is hereditary hemorrhagic telangiectasia; normal bleeding time and platelet count signify this is not immune (idiopathic) thrombocytopenic purpura (ITP).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 204%;text-align: left;">33M + non-smoker + worsening lung function + father died of alcoholic cirrhosis + younger brother is a smoker and has advanced lung disease; Q asks, the deficient enzyme in this patient normally targets what? <span class="s2">➔ </span>answer = elastase; Dx is a1-antitrypsin deficiency; codominant inheritance with varying degrees of severity; homozygous <i>ZZ </i>alleles cause severe presentation; a1-antitrypsin, despite the</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">name, breaks down elastase in the lungs; deficiency leads to <i>pan</i>-acinar emphysema (smoking causes centri-acinar); elastase also present in the liver, so cirrhosis common; presumption is father of this patient had greater susceptibility to alcoholic cirrhosis because of heterozygosity.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">42M + 7-month-Hx of shortness of breath on exertion + ejection fraction of 70% + Hx of epistaxis since adolescence + patient’s tongue and finger are shown; Q asks, what is cause of patient’s presentation?</p><p style="padding-left: 182pt;text-indent: 0pt;text-align: left;"><span><img width="312" height="139" alt="image" src="Image_034.png"/></span></p><ul id="l130"><li><p style="padding-top: 4pt;padding-left: 130pt;text-indent: -18pt;line-height: 206%;text-align: left;">Answer = “pulmonary arteriovenous shunting”; Dx is hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu); autosomal dominant; can cause GI bleeding (iron deficiency anemia; fatigue); Q will either show you a red dot on the tongue or finger (telangiectasia); can lead to high-output cardiac failure (EF &gt;70%) in middle age due to AV shunting (as with this patient);</p><p style="padding-top: 1pt;padding-left: 130pt;text-indent: 0pt;text-align: left;">vignette can also be pediatric.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">56M + HbA1c of 12% + decreased sensation to pinprick up to the ankles; Q asks, what’s the mechanism for myelinopathy in this patient? <span class="s2">➔ </span>answer = increased activity of aldose reductase; in diabetes, glucose moves into myelin sheaths and is converted to sorbitol via aldose reductase;</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">sorbitol causes osmotic damage due to cellular swelling.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">43M + gets sore knees when plays basketball + pinna of left ear slightly greyish + urine sample turns dark color upon standing; what enzyme is deficient in this patient? <span class="s2">➔ </span>answer = homogentisic acid (homogentisate) oxidase; required for tyrosine breakdown into fumarate (sometimes Q will ask which</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 211%;text-align: left;">amino acid is not broken down properly; answer = tyrosine); diagnosis is alkaptonuria; cartilage can turn dark in color (ochronosis); arthropathy can present (ochronotic arthropathy).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 200%;text-align: left;">12F + seizures + loss of vision + weakness + serum lactic acid increased + mother and maternal grandmother have hearing loss; where is the patient’s mutation? <span class="s2">➔ </span>answer = mitochondrial tRNA<span class="s15">Glu</span>; the point being: the kid has a mitochondrial disorder (classic findings of lactic acidosis, eye/ear problems, hypotonia/weakness), and mitochondrial tRNA<span class="s15">Glu</span><span class="s16"> </span>is the only answer that matches in this Q.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 195%;text-align: left;">Investigator looking at mutations in <i>NF1 </i>gene. A wildtype (healthy) sequence of 5’-ATGCCCCT-3’ <span class="s2">➔ </span>mutated sequence 5’-ATG<span class="s17">G</span>CCCT-3’; a restriction enzyme is designed to cleave the mutated sequence; what sequence will the restriction enzyme cleave at? <span class="s2">➔ </span>answer = 5’-GGCC-3’; most restriction enzymes cleave at palindromic sites (GGCC is a palindrome), versus, e.g., GCCC is still part of the</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">mutated sequence but is not a palindrome.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">Graph Q where the more protein A is bound to a plate, the less protein B is able to bind to the plate; Q asks why this is the case; answer = proteins A and B express the same epitope; epitope = part of an antigen that antibody attaches itself to; don’t confuse with antibody idiotype (Fab) and isotype (Fc), which I talk about in detail in HY Immuno.</p></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">34F + breast cancer + BRCA mutation; Q asks what kind of DNA repair is fucked up; answer = recombinational dsDNA break repair. In contrast, mismatch repair is answer for Lynch syndrome (HNPCC); nucleotide excision repair is xeroderma pigmentosum.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">69F + fractures right hip + two months later right leg has less muscle mass compared to left leg; which cellular process might explain these findings? <span class="s2">➔ </span>answer = polyubiquitination <span class="s2">➔ </span>atrophy entails protein breakdown, where ubiquitination of proteins targets them for the proteasome.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">25M + undergoing chemo for leukemia; a drug is given to help prevent renal failure; Q ask which enzyme this drug inhibits; answer = xanthine oxidase <span class="s2">➔ </span>allopurinol or febuxostat to prevent tumor lysis syndrome.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 199%;text-align: left;">1M + coarse facial features + hypotonia + increased serum lysosomal enzymes; which molecule is deficient in this patient? <span class="s2">➔ </span>answer = mannose-6-phosphate (easy for I-cell disease).</p></li><li><p style="padding-left: 94pt;text-indent: -90pt;line-height: 11pt;text-align: left;">Q shows you absurdly long sequence of DNA base pairs; exons are bolded; introns are un-bolded;</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">mutation is shown within an un-bolded region (i.e., an intron); Q asks what effect this would most likely have; answer = disruption of normal splicing; mutations within introns are sometimes splice-site mutations; for USMLE, just think: introns = do not become protein + mutations are often splice-site.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 213%;text-align: left;">Q asks about molecular effect of oxytocin; answer = increases phosphoinositide hydrolysis; oxytocin is G-alpha-q G-protein, which increases IP3 (via hydrolysis of PIP2) and DAG.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">Q asks which of the following analyses can help determine monoclonality of neoplastic cells; answer = X-chromosome-linked isoenzymes; isoenzymes are enzymes with different amino acid sequences that catalyze the same chemical reaction; monoclonality refers to a cancer originating from one cell; investigation of G6PD X-linked isoenzymes is a known method for determining clonality of cell populations. Weird and obscure, I get it. But it’s on the NBME.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: justify;">Bacterial strain produces a mutated protein that functions better at higher temperature; what kind of mutation accounts for this change in function; answer = missense mutation; polymorphisms resulting in differing function are usually missense – i.e., one amino acid is substituted for another.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 192%;text-align: left;">40F + high-anion-gap metabolic acidosis + blurry vision + hangs around paint thinner for fun; which molecule is responsible for the patient’s change in vision? <span class="s2">➔ </span>answer = formic acid; methanol <span class="s2">➔ </span>formaldehyde <span class="s2">➔ </span>formic acid; the latter can cause blindness with methanol toxicity; methanol is part</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">of MUDPILES for high-anion-gap metabolic acidosis (Methanol, Uremia, DKA, Phenformin, Iron/INH, Lactic acidosis, Ethylene glycol, Salicylates).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 213%;text-align: left;">Q mentions experiment involving abnormal elastin in lab animals; which amino acid is most likely to be abnormal in these lab animals; answer = lysine (need to know elastin contains lots of lysine).</p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Student says, “um ok...” I agree, dumb and pedantic, but it’s on NBME.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">82F + chronic alcoholism + tea and toast diet + blood around hair follicles + bruising; what process demonstrates decreased function in this patient? <span class="s2">➔ </span>answer = hydroxylation of proline; vitamin C is an essential cofactor for hydroxylation enzymes; required for collagen synthesis; perifollicular</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">hemorrhages, bleeding gums, and easy bruisability are common findings; “tea and toast” diet is non- specific and can be seen in many vitamin deficiencies; 2CK FM shelf says tea and toast for vitamin C; NBME for Step 1 doesn’t mention diet but says chronic alcoholism in a scurvy Q.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">12M + cystic fibrosis + ataxia + bilateral diminished reflexes + weakness of lower extremities; which vitamin is deficient (B12 not listed); answer = vitamin E; CF leads to fat-soluble vitamin malabsorption; vitamin E deficiency can present with neuropathy; other vitamin deficiencies causing neuropathy: B6 (answer for isoniazid use); B12 (pernicious anemia, chronic gastritis, gastrectomy, terminal ileectomy, Crohn disease, vegetarian/veganism, <i>Diphyllobothrium latum </i>infection); B1 (dry beriberi).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">30F + serum triglycerides 3200 mg/dL + serum appears milky; which enzyme is deficient in this patient? <span class="s2">➔ </span>answer = lipoprotein lipase (hyperchylomicronemia); if vignette also mentions lipase elevation and abdo pain, this is simply due to pancreatitis (i.e., the disease itself isn’t causing lipase</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">elevation); hyperchylomicronemia also caused by deficiency of apolipoprotein-CII.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">24M + high serum glucose + necrolytic migratory erythema; Q asks which process is most likely upregulated in this patient; answer = oxidation of fatty acids; glucagonoma will force patient into catabolic state (i.e., decreasing relative amount of insulin); in contrast, quick review of some HY wrong answers:</p><ul id="l131"><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 12pt;text-align: left;">“Decreased carnitine acyltransferase activity” <span class="s2">➔ </span>enzyme required for fatty acids to enter</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 130pt;text-indent: 0pt;text-align: left;">mitochondrion from cytosol, so this enzyme is catabolic and would be increased in activity.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 188%;text-align: left;">“Synthesis of glycogen” <span class="s2">➔ </span>clearly anabolic process and would not be increased in predominance of glucagon.</p></li><li><p style="padding-top: 3pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">“Increased acetyl-CoA carboxylase activity” <span class="s2">➔ </span>enzyme is anabolic and converts acetyl-CoA to</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 130pt;text-indent: 0pt;line-height: 212%;text-align: left;">malonyl-CoA, which is a precursor to fatty acid synthesis; this would not be upregulate in catabolic state; in addition, malonyl-CoA is the allosteric inhibitor of carnitine acyltransferase, meaning that if malonyl-CoA is increased, oxidation of fatty acids would be decreased, which is clearly not the case in the catabolic state.</p></li><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 13pt;text-align: left;">“Decreased ketogenesis” <span class="s2">➔ </span>we would expect increased, not decreased, ketogenesis in</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 130pt;text-indent: 0pt;line-height: 213%;text-align: left;">catabolic state. Acetyl-CoAs liberated from FA breakdown are the precursors for ketones in the catabolic state.</p></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">Guy starving in wilderness for three weeks + has decreased muscle mass; which of the following best explains his current status; answer = negative nitrogen balance; this means intake of nitrogen compounds (i.e., protein) is less than utilization by the body, leading to loss of muscle mass; in bodybuilding, a positive nitrogen balance ensures muscle growth.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">2M + fractures at different stages of healing + genetic mutation showing a glycine residue in the collagen I gene becomes an alanine; what’s the mechanism for this patient’s condition? <span class="s2">➔ </span>answer = weakening of secondary structure of collagen; glycine is a proton; alanine is a methyl group; this</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;line-height: 212%;text-align: left;">means if alanine replaces glycine, there’s less hydrogen bonding between sidechains in the collagen molecule (hydrogen bonding is important for secondary structure in proteins); I often see students memorizing “Ok, osteogenesis imperfecta is deceased secondary structure.” But this isn’t the point. The Q is assessing your understanding of amino acids, hydrogen bonding, and secondary structure.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">Q asks for important effect of niacin on patient with increased serum TGAs; answer = antagonizes hepatic VLDL-cholesterol secretion (i.e., decreases TGAs); niacin notably increases HDL (not listed as an answer for this Q + the Q asks about a patient who specifically has high TGAs); PPAR-alpha agonism refers to fibrates (upregulate lipoprotein lipase).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">4M + recurrent pancreatitis + high serum cholesterol and TGAs + receives an injection of heparin and this restores his serum lipoprotein lipase activity; which of the following is decreased in this patient; answer = ApoC-II; familial hyperchylomicronemia.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 202%;text-align: left;">Q asks about how to counsel healthy patient on good nutrition; what should be part of this patient’s diet? <span class="s2">➔ </span>answer = linoleic and linolenic acids (the two essential unsaturated fatty acids); linoleic is</p><p style="padding-top: 4pt;padding-left: 94pt;text-indent: 0pt;line-height: 213%;text-align: left;">omega-6; linolenic is omega-3; both are C18; wrong answer is stearic acid (C18 saturated FA that shows up frequently as distractor for biochem NBME Qs).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 213%;text-align: left;">Q asks about cellular effect of <i>Diphtheria </i>toxin; answer = disrupts translation; inhibits elongation factor 2; (same as <i>Pseudomonas</i>).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Q asks about impaired trafficking of vesicles into the Golgi; which would be seen on electron</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 181%;text-align: left;">microscopy of the cell? <span class="s2">➔ </span>answer = rough endoplasmic reticulum dilatation; normally proteins are trafficked from RER <span class="s2">➔ </span>Golgi, so if this process cannot occur, the RER should dilate.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">Q asks about what kind of protein alteration will result in failure of protein transport within a cell; answer = deletion of residue from N-terminus; signal-recognition particles that enable cellular trafficking of proteins recognize the N-termini of proteins; if the N-terminus is disrupted on a protein, the SRP cannot target the protein to its correct cellular destination. Pedantic? Right. Well it’s on NBME.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;text-align: left;">Q asks about where the receptor for signal-recognition particles is located; answer = RER.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 213%;text-align: justify;">Q asks about which amino acid is necessary in a healthy child’s diet in order to maintain proper nutrition; answer = methionine (essential amino acid); essential amino acid; memorize for USMLE.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: justify;">27F + lost in wilderness + normoglycemia even after 3 weeks; which amino acid is likely to contribute to normal serum glucose in this patient? <span class="s2">➔ </span>answer = alanine; the four main gluconeogenic substrates in humans are lactate, glycerol, alanine, glutamine.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 214%;text-align: left;">Acute myocardial infarction; Q asks about what we’d expect in the ischemic cells in terms of intracellular sodium, intracellular potassium, and intracellular calcium; answer = t intracellular Na, --1 intracellular potassium, t intracellular Ca. Normally the Na/K-ATPase pumps out 3Na + pumps in 2K for every 1ATP utilized. If Na builds up within the cell, this indirectly inactivates the Na/Ca antiporter (Na in; Ca out), since the gradient is no longer favored for Na; this results in more Ca staying within the cell. This is the same mechanism via which digoxin works (i.e., inhibits Na/K-ATPase, resulting in indirect inactivation of Na/Ca-ATPase).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">2M + Hx of viral, fungal, bacterial, protozoal infections; investigations show a buildup of dATP in the patient’s cells; this buildup inhibits which of the following enzymes? <span class="s2">➔ </span>answer = ribonucleotide reductase; child has AR form of SCID, resulting in adenosine deaminase (ADA) deficiency; ADA</p><p style="padding-top: 1pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">deficiency causes a buildup of dATP, which inhibits ribonucleotide reductase (on Step 1 NBME).</p></li><li><p style="padding-top: 3pt;padding-left: 94pt;text-indent: -18pt;line-height: 183%;text-align: left;">Girl eats a meal; what’s the mechanism of insulin secretion in her? <span class="s2">➔ </span>answer = fusion of vesicle with cell membrane; insulin secretion requires ATP-mediated closure of K channel <span class="s2">➔ </span>K builds up in the cell</p><ul id="l132"><li><p style="padding-left: 106pt;text-indent: -12pt;line-height: 13pt;text-align: left;">depolarization <span class="s2">➔ </span>causes Ca influx <span class="s2">➔ </span>vesicles filled with insulin fuse with plasma membrane <span class="s2">➔</span></p></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;text-align: left;">insulin exocytosed.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -75pt;text-align: left;">5F + cystic fibrosis; Q asks, defect in which of the following is responsible for her condition <span class="s2">➔ </span>answer</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 211%;text-align: left;">= protein structure; the chloride channel has defective protein structure, resulting in sequestration within the RER of the cytosol (i.e., channel is <i>not </i>transported to cell surface).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 197%;text-align: left;">Q asks which substrate is required to synthesize glucosamine from fructose-6-phosphate; answer = glutamine (yes, this is asked as a one-liner); F6P + glutamine <span class="s2">➔ </span>glucosamine + glutamate; glucosamine is a precursor for glycoproteins, glycolipids, and proteoglycans.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -73pt;text-align: left;">Two different Qs asking about G-proteins; first asks effect of albuterol; other asks effect of ranitidine;</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l133"><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">Albuterol <span class="s2">➔ </span>beta-2 agonist <span class="s2">➔ </span>agonizes G-alpha-s <span class="s2">➔ </span>increased cAMP.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">Ranitidine <span class="s2">➔ </span>antagonizes histamine-2 <span class="s2">➔ </span>antagonizes G-alpha-s <span class="s2">➔ </span>decreased cAMP.</p></li></ul></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 25pt;text-align: left;">TATA box is mutated within a gene; what is the result of this? <span class="s2">➔ </span>answer = decreased binding of RNA polymerase; TATA box is region within the promotor region where RNA polymerase II binds to initiate transcription.</p></li><li><p style="padding-top: 8pt;padding-left: 94pt;text-indent: -18pt;line-height: 191%;text-align: left;">54F + temporal arteritis + IV methylprednisolone administered; how does this drug bind? <span class="s2">➔ </span>answer = cytosolic receptor with translocation to the nucleus; most steroid hormones bind cytosolic receptors,</p><p style="padding-top: 2pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">followed by translocation to the nucleus where gene transcription is upregulated.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">Investigator looking at organism that has incurred RNA polymerase mutation; why will this not adversely affect the species survival <span class="s2">➔ </span>answer = transcriptional errors are not transmitted to progeny.</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 206%;text-align: left;">Investigator looking at plasma-membrane-associated proteins vs those that are secreted from the cell; which of the following is most likely to be observed to be different between these types of proteins <span class="s2">➔ </span>answer = transmembrane domain (present in plasma-membrane-associated proteins).</p></li><li><p style="padding-left: 94pt;text-indent: -70pt;line-height: 10pt;text-align: left;">Neonate + jaundice + hypoglycemia + reducing sugars seen in urine; assay for which of the following is</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 192%;text-align: left;">most likely to establish the diagnosis <span class="s2">➔ </span>answer = activity of galactose-1-phosphate uridyltransferase (classic galactosemia).</p></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">G-protein signaling is disrupted in a patient; the effect of which of the following is most likely to be attenuated? <span class="s2">➔ </span>answer = epinephrine (since agonizes adrenergic receptors, which are G-protein- coupled).</p></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 204%;text-align: left;">3% saline is administered to a patient; what will happen to both osmolality and volume within the ECF and ICF? <span class="s2">➔ </span>answer = t ECF volume; t ECF osmolality; --1 ICF volume; t ICF osmolality; 3% is hypertonic (isotonic = 0.9%); t osmolality of ECF will cause fluid shift out of ICF compartment, thereby increasing osmolality of ICF.</p><ul id="l134"><li><p style="padding-top: 1pt;padding-left: 130pt;text-indent: -18pt;line-height: 198%;text-align: left;">Administration of hypotonic saline: t ECF volume; --1 ECF osmolality; t ICF volume; --1 ICF osmolality.</p></li><li><p style="padding-top: 3pt;padding-left: 130pt;text-indent: -18pt;line-height: 198%;text-align: left;">Administration of isotonic saline: t ECF volume; no change ECF osmolality; no change ICF volume; no change ICF osmolality.</p></li></ul></li><li><p style="padding-top: 1pt;padding-left: 94pt;text-indent: -18pt;line-height: 187%;text-align: left;">Cortisol increases synthesis of which of the following enzymes? <span class="s2">➔ </span>answer = phenylethanolamine N- methyltransferase (converts NE <span class="s2">➔ </span>E); norepinephrine and cortisol share venous drainage from the medulla, where conversion to epinephrine occurs.</p></li><li><p style="padding-top: 2pt;padding-left: 94pt;text-indent: -18pt;line-height: 198%;text-align: left;">Neonate has progressive lethargy + hypotonia + metabolic acidosis + hyperammonemia; what type of condition is most likely responsible? <span class="s2">➔ </span>answer = organic acid metabolism disorder; common type is methylmalonic acidemia; organic acids, such as methylmalonic acid, can disrupt urea cycle (--1</p><p style="padding-top: 2pt;padding-left: 94pt;text-indent: 0pt;text-align: left;">conversion of ammonia to urea); the acids themselves --1 pH.</p></li><li><p style="padding-top: 11pt;padding-left: 94pt;text-indent: -18pt;text-align: left;">How to overcome methotrexate toxicity? <span class="s2">➔ </span>leucovorin rescue (folinic acid; <i>not </i>folic acid).</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;text-align: left;">How to overcome 5-FU toxicity <span class="s2">➔ </span>oral thymidine or uridine.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 183%;text-align: left;">What two substrates are required for heme synthesis? <span class="s2">➔ </span>answer = glycine and succinyl-CoA (combine via B6 and delta-ALA synthase <span class="s2">➔ </span>delta-ALA as first step in heme synthesis).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 192%;text-align: left;">What best explains altered mental status in diabetic ketoacidosis? <span class="s2">➔ </span>answer = dehydration both intra- and extracellularly (polyuria causing fluid depletion).</p></li><li><p style="padding-top: 2pt;padding-left: 94pt;text-indent: -18pt;line-height: 206%;text-align: left;">Investigator looking at a protein that serves as a precursor for various hormones; which of the following molecular processes is required in order to generate the hormones from the precursor protein? <span class="s2">➔ </span>answer = post-translational modification.</p></li><li><p style="padding-top: 4pt;padding-left: 94pt;text-indent: -18pt;text-align: left;">Patient with terminal ileectomy; which of the following molecular processes is most likely to be</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 187%;text-align: left;">disrupted? <span class="s2">➔ </span>answer = conversion of N<span class="s15">5</span>-methyltetrahydrofolate to tetrahydrofolate; vitamin B12 is required for conversion of uracil <span class="s2">➔ </span>thymine, as a methyl group is transferred to uracil in order to make thymine.</p><ul id="l135"><li><p style="padding-top: 1pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">1) Homocysteine + 5-methyl-THF, via B12 <span class="s2">➔ </span>methionine + THF</p></li><li><p style="padding-top: 10pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">2) Methionine + ATP <span class="s2">➔ </span>SAM</p></li><li><p style="padding-top: 10pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">3) SAM donates -CH3 elsewhere <span class="s2">➔ </span>homocysteine</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 212%;text-align: left;">Patient has peripheral neuropathy + normal MCV + decreased hemoglobin + increased LDH; Q asks for vitamin deficiency (B12 and E both listed); answer = vitamin E deficiency. Increased serum LDH can be seen with hemolysis / RBC turnover; vitamin E deficiency can lead to RBC fragility and hemolysis. B12 deficiency causes increase in MCV.</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 196%;text-align: left;">Neonate + jaundice + increased LFTs + increased serum very-long-chain fatty acids; which organelle is the site of the defect? <span class="s2">➔ </span>answer = peroxisome (required for very-long-chain and branched-chain FA breakdown).</p></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 192%;text-align: left;">Which phase of the cell cycle are mitotic cyclins synthesized? <span class="s2">➔ </span>answer = G2 (preparation for mitosis). Cell cycle phases are G1, S, G2, M. Interphase comprises G1, S, G2; mitotic phase is M.</p><ul id="l136"><li><p style="padding-top: 1pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">G1 <span class="s2">➔ </span>cellular contents (excluding chromosomes) are duplicated.</p></li><li><p style="padding-top: 10pt;padding-left: 130pt;text-indent: -18pt;text-align: left;">S <span class="s2">➔ </span>DNA synthesis (46 chromosomes duplicated by the cell).</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">G2 <span class="s2">➔ </span>more cell growth + mitotic cyclin synthesis.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">M <span class="s2">➔ </span>mitosis + cytokinesis; nuclear envelope proteins phosphorylated during cytokinesis.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ul></li><li><p style="padding-left: 94pt;text-indent: -18pt;line-height: 191%;text-align: left;">Neonate + lactic acidosis + ketonemia + hypoglycemia; fructose + glycerol fail to increase glucose levels; galactose does increase glucose levels; what kind of defect does this patient have? <span class="s2">➔ </span>answer = defect in gluconeogenesis; galactose <span class="s2">�➔ </span>galactose-1-phosphate <span class="s2">�➔ </span>galactose-6-phosphate <span class="s2">�➔</span></p><p style="padding-left: 94pt;text-indent: 0pt;line-height: 12pt;text-align: left;">glucose-6-phosphate; the latter, via glucose-6-phosphatase <span class="s2">➔ </span>glucose.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ul id="l137"><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">Glycerol <span class="s2">➔ </span>dihydroxyacetone phosphate (DHAP) <span class="s2">�➔ </span>F-1,6-BP <span class="s2">➔➔ </span>glucose.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;text-align: left;">Fructose <span class="s2">➔ </span>F-1-phosphate <span class="s2">➔ </span>dihydroxyacetone phosphate <span class="s2">�➔ </span>F-1,6-BP <span class="s2">➔➔ </span>glucose.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p style="padding-left: 130pt;text-indent: -18pt;line-height: 204%;text-align: left;">You can see the entrance of galactose into glycolytic intermediates (i.e., G6P) is closer in proximity to glucose, so there must be a defect between DHAP and G6P in the aforementioned patient.</p></li></ul></li></ul><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 252pt;text-indent: 0pt;text-align: left;"><span><img width="90" height="95" alt="image" src="Image_035.jpg"/></span></p><h1 style="padding-top: 6pt;padding-left: 170pt;text-indent: 62pt;line-height: 122%;text-align: left;">YouTube @mehlmanmedical</h1><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 253pt;text-indent: 0pt;text-align: left;"><span><img width="89" height="95" alt="image" src="Image_036.jpg"/></span></p><h1 style="padding-top: 6pt;padding-left: 163pt;text-indent: 61pt;line-height: 122%;text-align: left;">Instagram @mehlman_medical</h1><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 250pt;text-indent: 0pt;text-align: left;"><span><img width="89" height="92" alt="image" src="Image_037.jpg"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-top: 11pt;padding-left: 143pt;text-indent: 0pt;line-height: 122%;text-align: center;">MEHLMANMEDICAL HY BIOCHEMISTRY</h1><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s38" style="padding-left: 79pt;text-indent: 0pt;text-align: center;">All material is copyrighted and the property of mehlmanmedical.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-left: 79pt;text-indent: 0pt;text-align: center;">Copyright © <u>mehlmanmedical</u></p></body></html>
